Editorial Board Profiles


  • Julio E. Celis

    Professor and Associated Scientific Director, Danish Cancer Society Research Center, Copenhagen, Denmark

    E-mail: jec@cancer.dk

Julio E. Celis was Director of the Institute of Cancer Biology at the Danish Cancer Society until the end of 2011, and is currently Associate Scientific Director of the Danish Cancer Society Research Center. Prof Celis has been Chairman of the European Molecular Biology Laboratory Council, Vice President of the Human Proteome Organization, Chair of the Initiative for Science in Europe, President of the European Molecular Biology Conference, Secretary General of the Federation of European Biochemical Societies, President of the European Life Sciences Forum, President of the European Association for Cancer Research, Chairman of the Policy Committee at the European CanCer Organisation, and Vice-President of the Alliance for Biomedical Research in Europe. He is currently Advisor to the Scientific Panel for Health in H2020, member of the European Commission Research, Innovation and Science Experts (RISE) High-Level Advisory Board, Chair of the Science Policy committee of the European Academy of Cancer Sciences, Advisor to the board of Cancer Core Europe, and Editor-in-Chief of Molecular Oncology. Prof Celis is a Foreign Member of the Royal Danish Academy of Sciences and Letters, and member of the European Molecular Biology Organization, the Academia Europaea, and the European Academy of Cancer Sciences. He is generally recognized as one of the founding fathers of proteomics, and played an important role in the steps leading to the creation of the European Research Council.

Senior Associate Editors

A-L Børresen-Dale has a large scientific production of more than 300 papers and books and is among the leading geneticists in research on molecular biology of breast cancer. She came to the Cancer Research Institute, Department of Genetics in 1987 and under her leadership a novel mutation detection systems was developed, and further used for screening for TP53 mutations in large series of tumours, showing that mutations in this gene are relevant for prognostic evaluation, progression of the disease and prediction of therapy response. In collaboration with the Professors D. Botstein and P. Brown, Stanford University, California, she performed pioneering work on expression profiling of breast tumours using genome wide microarrays. They identified 5 distinct subtypes of breast cancer (luminal subtypes A and B, a basal-like subtype, an ERBB2 and a normal like subtype), that were associated with significant differences in survival. This was a fundamentally important discovery. She has received several prizes and awards; the two most recent being the SalusAnsvar Medical prize for Outstanding Research in Tumor biology in 2002, and the Swiss Bridge Award for outstanding Cancer Research in 2004. She is also an elected Member of The Royal Norwegian Academy of Science and of the Norwegian Academy of Science and Letters. . Børresen-Dale has served on the Board of Directors for AACR and is currently President Elect for EACR.

  • Ulrik Ringborg

    Senior Professor of Oncology at the  Karolinska Institute, and Director of the Cancer Center Karolinska, Stockholm, Sweden

Website: http://www.karolinska.se
E-mail: ulrik.ringborg@ki.se

Dr Ulrik Ringborg is Senior Professor of oncology at the Karolinska Institutet and director of the Cancer Center Karolinska, the translational cancer research structure at the Karolinska. Main research interest has focused on malignant melanoma. He has a special interest in structuring translational cancer research. Dr Ringborg has had several international missions, among them president of the Organisation of European Cancer Institutes and at present secretary general of the European Academy of Cancer Sciences. He was a member of the Nobel Assembly. At present he is coordinating the EurocanPlatform project aiming at a European translational cancer research platform. An outcome of the EurocanPlatform project is the Cancer Core Europe. He has published about 300 scientific papers.

  • José Moreira

    Managing Editor, Molecular Oncology

José Moreira studied Biochemistry at O'Porto University and obtained a Ph.D. in Molecular Biology from the University of Copenhagen based on his thesis work on chromatin-mediated transcriptional regulation of genes in Saccharomyces cerevisiae. Dr. Moreira's early research was focused on the regulatory constraints that chromatin structure imposes on the various cellular processes, and during that period he made significant contributions to our understanding of the interplay between chromatin modulation and transcriptional regulation. In 1999 he took an industrial postdoctoral fellow position with Active Biotech Research AB (Lund, Sweden) a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative immunotherapy's for several diseases, including cancer.

Since 2002, Dr. Moreira has been a Senior Scientist at the Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, where he has devoted his research efforts to a global breast cancer project (Danish Center for Translational Breast Cancer Research- DCTB) aimed at identifying biomarkers and therapeutic markers for breast cancer.

Editorial Board

Prof. Aebersold is a native of Switzerland and a Swiss and Canadian citizen. He obtained his Ph.D. in Cellular Biology at the Biocenter of the University of Basel in 1983. He was a faculty member at the University of British Columbia, from 1988 till 1994 and then a faculty member at the University of Washington in Seattle till 2000 when he co-founded the Institute for Systems Biology in Seattle. In 2004, he accepted a position as professor at the Swiss Federal Institute of Technology (ETH) in Zurich and the University of Zurich.

Prof. Aebersold is one of the pioneers in the field of proteomics. He is known for developing a series of methods that have found wide application in analytical protein chemistry and proteomics, such as a new class of reagents termed Isotope Coded Affinity Tag (ICAT) reagents used in quantitative mass spectrometry. Prof. Aebersold and his team of researchers use the protein profiles determined by this method to differentiate cells in different states, such as noncancerous versus cancerous cells, and to systematically study how cells respond to external stimuli. These "snapshot" profiles indicate which cells contain abnormal levels of certain proteins. This is expected to lead to new diagnostic markers for disease and to a more complete understanding of the biochemical processes that control and constitute cell physiology. Prof. Aebersold's group has also pioneered the use of statistical models to determine the false discovery rates of peptide and protein identification in proteomic studies. These algorithms and the software tools that implement them are in use in more than 1000 laboratories worldwide. Recognizing that systems biology research is starved for high quality datasets that describe biological systems, the focus of his research is on the development and the application of new proteomics technologies. These technologies aim at detecting and quantifying the proteins and their interactions at the level of the complete proteome. Specific applications of the technology are directed towards the understanding of biological processes and the detection and validation of protein biomarkers for the early detection, diagnosis and classification of disease.

Prof. Aebersold serves on the Scientific Advisory Committees of numerous academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics. He is the recipient of numerous awards for his contribution to the field of protein sciences and proteomics including the ABRF Award (2008), the FEBS Buchner Medal (2006), and the HUPO Award (2005), the ASBMB Biemann medal (2002) the Widmer award (2002) the ASBMB Herbert Sober award (2009) the Otto Naegeli Prize (2009) and the 2003 World Technology award. He has published more than 500 peer reviewed papers and reached an h-factor of 98.

Dr Kari Alitalo (born 1952) is a tenured Research Professor of the Finnish Academy of Sciences and the Director of the Molecular/Cancer Biology Program and Centre of Excellence in the University of Helsinki, Finland. He obtained an M.D. (1977) and a Ph.D. (1980) from the University of Helsinki. During his postdoctoral period in 1982-1983 Dr. Alitalo worked with Drs. J. Michael Bishop and Harold E. Varmus in San Francisco. Dr. Alitalo has discovered several novel receptor tyrosine kinases, important in particular in endothelial cells. He has shown that some of these receptors and their ligands play important roles in tumor angiogenesis. Among the original findings are the cloning and characterisation of fibroblast growth factor receptor-4, the C-terminal Src tyrosine kinase and the first endothelial specific receptor tyrosine kinase, Tie, as well as VEGFR-3 and the cloning and characterization of VEGF-B in collaboration with Dr. Ulf Eriksson and determination of VEGFR-1 and NP-1 as its receptors. A significant achievement by Dr. Alitalo was the isolation, cloning and characterization of the first lymphangiogenic growth factor VEGF-C and isolation of lymphatic endothelial cells, opening up the lymphatic vascular system to molecular analysis after over a hundred years of descriptive pathology. He has also been central in the characterization of VEGF-B, VEGF-C and VEGF-D receptors and signal transduction pathways and the function of VEGFR-3, showing that this receptor is required for angiogenesis and later in lymphangiogenesis in embryos. He has devised molecular therapies for lymphedema that are now entering clinical trials. He furthermore demonstrated that VEGF-C is overexpressed in tumors and its receptor VEGFR-3 is upregulated in angiogenic tumor vasculature. His studies led to the demonstration of VEGF-C associated tumor lymphangiogenesis, intralymphatic tumor growth, and VEGF-C association with tumor metastasis and its inhibition by blocking the VEGFR-3 signal transduction pathway. Dr. Alitalo has published more than 330 research articles and 100 reviews, and has received several scientific awards, including Leopold Griffuel Prize (2003), Eric K Fernström Foundation's Nordic Prize (2005) and Louis-Jeantet Prize For Medicine (2006).

Geneviève Almouzni received a PhD in Microbiology from the Université Pierre et Marie Curie, Paris, France, in 1988. After a postdoctoral visit at the National Institutes of Health, Bethesda, USA, in the laboratory of Alan P. Wolffe to deepen her expertise in chromatin studies, she established her own independent research on chromatin dynamics as a junior group leader holding a CNRS (Centre National de la Recherche Scientifique) position at the Institut Curie, Paris, France, in 1994. Further, she has been appointed as head of the Nuclear Dynamics and Genome Plasticity unit, a mixed struture beteween the Institut Curie and the CNRS in 1999. Since 2009, she has also taken the responsibility of Deputy Director in charge of advanced training for the Research center at the Institut Curie.

Her group over the years has conducted research on chromatin dynamics, histone variants, histone chaperones and nuclear organization with a particular interest on heterochromatin. Her general objective has been to dissect the mechanisms of chromatin assembly, from the basic structural unit, the nucleosome, up to the higher-order structures in the nucleus. Her lab has characterized key chaperones involved in nucleosome assembly and defined the dynamics of new histone incorporation in chromatin. In addition, her work on specific nuclear domains has unveiled the importance of non-coding centromeric heterochromatic regions, which are of major importance for chromosome segregation and relevant for cancer. These findings have shed light on the fundamental issues of the dynamics, fate, and inheritance of histones, with their specific marks typical of particular chromatin domains. In addition, her lab found that misregulation of specific histone chaperones is a common feature of aggressive breast cancers. Her lab has exploited a variety of tools and models to understand the in vivo functions of chromatin dynamics (e.g. Xenopus, mouse) that combine biochemistry, cell biology, and developmental biology. These integrated approaches from molecules to tissue and a whole organism are actively pursued.

In addition to her scientific work, she has participated in structuring research in Epigenetics in Europe to promote young scientists by her involvement in several networks, including the Epigenome European network (www.epigenome-noe.net/WWW/index.php), and more recently, the network of excellence EpiGeneSys, to move epigenetics towards system biology (www.epigenesys.org) for which she acts as the scientific coordinator.

Dr. Almouzni serves on the Scientific Advisory Committees of numerous research organizations and is a member of several editorial boards in the fields of epigenetics, chromatin and development. She is the recipient of several awards for her contribution to the fields of epigenetics, chromatin and development including the CNRS Silver Medal (2003), the Ligue Contre le Cancer Prize (2003), the Cino et Simone del Duca Fondation Special Scientific Prize by the Institut de France (2006), the Louis D. Fondation Special Scientific Prize on Epigenetics by the Institut de France (2011) and the FEBS/EMBO Women in Science Award (2013). She has published more than 160 peer reviewed papers.

Mariano Barbacid is Director of the Spanish National Cancer Research Centre (CNIO), a new institute in Madrid that he helped to put together in the late 90's, after spending 23 years in the US. In 1982, he led one of three groups that isolated the first human oncogene (H-Ras) and unveiled its mechanism of activation. Other contributions of special relevance include the identification in 1991 of the Trk family of tyrosine protein kinases –previously discovered in his group in the mid 80's– as the receptors for the NGF family of neurotrophic factors. Since his return to Spain, the Barbacid lab has concentrated on designing new animal models that closely recapitulate the natural history of human cancers and in studying the role of Cdks in the regulation of the cell cycle. This work has challenged the classical model of the mammalian cell cycle by demonstrating that the G1/S cyclin-dependent kinases are dispensable for cell division. The relevance of his work has been recognised by several awards, including the Young Investigator Award of the American Association of Cancer Research (USA, 1986), Steiner Prize (Switzerland, 1988), Ipsen Prize (France, 1994) and the Brupbaher Cancer Research Prize (Switzerland, 2005). He became an Associate Member of EMBO in 1996.

  • Alberto Bardelli
  • Alberto Bardelli

    Associate Professor at University of Torino, Dept. of Oncology and Director of the Laboratory of Molecular Genetics at the Candiolo Cancer Institute-IRCCS, Candiolo (Torino).

    E-mail: alberto.bardelli@ircc.it

Prof Bardelli received a PhD in Biochemistry and Molecular Biology at UCL (London, UK) in 1996. As a post doc at the Howard Hughes Medical Institute at the Johns Hopkins University (Baltimore, USA), in the group led by Bert Vogelstein, he has developed the first comprehensive mutational profile of kinases in CRCs. As an independent investigator Prof Bardelli has then translated these findings into clinical practice by discovering that K-RAS (B-RAF) mutations impart resistance to EGFR-targeted agents. These findings were later confirmed by independent laboratories with such compelling evidence that they were rapidly translated into clinically applicable predictive biomarkers (genomic signatures) currently used to select patients for anti EGFR therapy. Recently, prof. Bardelli’s work has defined mechanisms of acquired resistance to anti EGFR therapies in colorectal cancer patients thus providing insights into new therapies aimed at overcoming resistance. These studies involve an innovative methodology - named liquid biopsy - which allows the use of circulating tumor DNA to monitor patient’s response using a blood draw.

  • Jiri Bartek

    Danish Cancer Society, Copenhagen, Denmark

    E-mail: jb@cancer.dk

Jiri Bartek is the Head of the Department of Cell Cycle and Cancer, and Deputy Director of the Centre for Genotoxic Research, at the Institute of Cancer Biology, Danish Cancer Society in Copenhagen, EMBO member and honorary Professor at the Universities of Aarhus and Copenhagen. After obtaining his MD and PhD degrees at the Palacky University in Olomouc and the Institute of Molecular Genetics in Prague, respectively, he worked at several European cancer institutes including the Imperial Cancer Research Fund Laboratories in London and German Cancer Research Center in Heidelberg, before taking up his present position in Copenhagen. His main research interests include molecular mechanisms of mammalian cell cycle control, coordination of DNA damage signaling with cell cycle checkpoints and DNA repair pathways, as well as the roles of these mechanisms as tumorigenesis barriers and their defects during cancer development.

Jose Baselga

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY USA

E-mail: baselgaj@mskcc.org

  • Stephen Baylin

    Deputy Director
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD USA

    E-mail: sbaylin@jhmi.edu

For the last 20 years, Prof. Stephen Baylin has studied the role of epigenetic gene silencing in the initiation and progression of human cancer. He and his colleagues have fostered the concept that DNA hypermethylation of gene promoters, and associated transcriptional silencing, can serve as an alternative to mutations for producing loss of tumor suppressor gene function. They have described some of the classic genes involved, invented approaches to randomly screen the cancer genome for such genes and to demonstrate their functional role in cancer progression, helped begin unravel the molecular mechanisms responsible for the initiation and maintenance of the gene silencing, and worked to utilize all of their findings for translational purposes. Dr. Baylin has authored or co-authored over 350 full-length publications on the above and other areas of cancer biology.

Dr. Baylin is currently Deputy Director, Professor of Oncology and Medicine, Chief of the Cancer Biology Division and Director for Research, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He has been a member of committees of the American Cancer Society and of NIH, and his honors include a Research Career Development Award from NIH, the Edwin Astwood Lectureship of the Endocrine Society, the 2003 Jack Shultz Memorial Lecture in Genetics, Fox Chase Cancer Center, The 2004 National Investigator of the Year Award from the NCI SPORE program, the Jack Gibson Visiting Professorship, University of Hong Kong Queen Mary Hospital, Hong Kong, The 2004 2nd Annual Sydney E. Salmon Lectureship in Translational Research, Arizona Cancer Center, the 2005 Shubitz Cancer Research Prize from the University of Chicago, and he currently holds the Virginia and D.K. Ludwig Chair in Cancer Research at Johns Hopkins. Dr. Baylin is also recipient of the 2007 Woodward Visiting Professor, Memorial Sloan-Kettering Cancer Center, the 2008 Raffaele Tecce Memorial Lecture, Trento, Italy, the 2008 The David Workman Memorial Award (jointly with Peter A. Jones, Ph.D.) from the Samuel Waxman Foundation, and the 2009 Kirk A. Landon-AACR Prize for Basic Cancer Research, also shared with Peter A. Jones, the 14th NCI Alfred G. Knudson Award in Cancer Genetics, and, most recently, the Nakahara Memorial Lecture prize at the 2010 Princess Takematsu Symposium. Currently, he leads, with Peter A. Jones, the Epigenetic Therapy Stand Up to Cancer Team (SU2C).

  • René Bernards

    Professsor, Dr.
    Head of the Division/Group Leader
    Molecular Carcigonesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    E-mail: r.bernards@nkl.nl

René Bernards received his Ph.D. in 1984 from the University of Leiden. He joined the laboratory of Robert Weinberg at the Whitehead Institute in Cambridge, USA for his postdoctoral training. Here, he studied the function of both oncogenes and tumor suppressor genes. He continued this work when he joined the Massachusetts General Hospital Cancer Center as an assistant professor in 1988. In 1992 he was appointed senior staff scientist at the Netherlands Cancer Institute. In 1994 he was appointed part time professor of molecular carcinogenesis at Utrecht University, The Netherlands. In the last decade, his laboratory has focused on the development of new tools to carry out genome-wide loss-of-function genetic screens to identify novel genes that act in cancer-relevant pathways. In July of 2003 he co-founded "Agendia", a genomics-based diagnostic company that started offering the first microarray-based diagnostic test for the clinical management of breast cancer in 2004. He received several awards for his research, including the Pezcoller Foundation-FECS Recognition for Contribution to Oncology, the Ernst W. Bertner Award for Cancer Research from the M.D. Anderson Cancer Center, the ESMO Lifetime Achievement Award in Translational Research in Breast Cancer and the Spinoza award from the Netherlands Organization for Scientific Research. He is a member of the Royal Netherlands Academy of Arts and Sciences.

Anton Berns studied biochemistry at the University of Nijmegen and received his Masters degree in 1969 and his PhD in 1972 from that same University. He did his postdoctoral training in the group of Rudolf Jaenisch at the Salk Institute in La Jolla, CA, where he studied the role of retroviruses in causing lymphomas in mice. In 1976 he returned to the University of Nijmegen where he became junior staff member. His group explored proviral insertional mutagenesis as a means to identify new oncogenes. In 1985 he was appointed as staff scientist at the Netherlands Cancer Institute and in 1986 he became head of the Division of Molecular Genetics of the Institute. Here his group did pioneering work to generate and utilize genetically modified mice as a tool to search for new cancer genes. Currently, his group focuses on the development and use of advanced mouse models for cancer. Themes of his current research are: i. Establishing genotype-phenotype correlations of tumors using Cre-mediated switching of multiple oncogenes/tumor suppressor genes in a spatiotemporal controlled fashion with emphasis on lung cancer models, and ii. The use of high throughput proviral insertional mutagenesis to identify components in signaling pathways relevant for cancer. His group consists of approximately 12 post-docs and graduate students. In 1999, he was appointed as Director of Research and Chairman of the Board of Directors of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital.

Professor Mina Bissell is a Distinguished Scientist (Nov 2002-) at Lawrence Berkeley National Laboratory (LBNL), University of CA (UC), Berkeley, CA, where she is also Senior Advisor to the Laboratory Director on Biology (Nov. 2002-), a member of 3 graduate groups at UC Berkeley, and a member of the Faculty, Breast Oncology Program, UCSF (2006-).

Professor Bissell gained a B.A. (Honors) in Chemistry from Radcliffe/Harvard College (1963) and an M.A. (1964) and Ph.D. from Harvard University Medical School in Microbiology and Molecular Genetics (1969). Previous research experience and employment includes: Visiting Wellcome Professor, Kettering Institute, University of Cincinnati Medical School (1986-88); Director, Cell and Molecular Biology Division, LBNL (1988-92); Director, Life Sciences Division (includes Cell and Molecular Biology Division), LBNL (1992-2002); Associate Director, Biosciences, LBNL (1995-2002).

She has received numerous awards and honors, including the Lawrence Award and Medal; President, American Society of Cell Biology (1997); Election to the Institute of Medicine of National Academies (IOM); Honorary Doctorate, Pierre & Marie Curie University, Paris, France (2001); Innovator Award in Breast Cancer, US Department of Defense (2002); Elected to the American Academy of Arts and Sciences (2002); Honorary Doctorate, University of Copenhagen (2004); Distinguished Scientist Award, OBER, US Dept. of Energy (2005); Ted Couch Lectureship and Award in Cancer Research, H. Lee Moffitt Cancer Center and Research Institute (2007); Pezcoller Foundation - AACR International Award for Cancer Research (2007); Election to the American Philosophical Society (2007); more than 80 distinguished and named lectures.

Professor Bissell has served on many national and international committees and review boards, including: Chair, 2 Gordon Research Conferences and 2 Keystone Conferences (1993, 96, 98, 2005); 4 NIH Study Sections; NCI Panel on "Preclinical Models of Cancer" (1997-98); Board of Directors, AACR (1999-2001); Breakthrough Breast Cancer, London, UK (2002-); Nominating Committee, AACR (2006-2008).

She is currently Associate Editor and member of the Editorial Boards of 15 journals including: Journal of Cell Science (2006-); Science (2005-); The FASEB Journal (2002-); Breast Cancer Research (1999- Senior Editor). She has authored more than 250 original papers and has had 5 patents issued.

Cédric Blanpain

Cédric Blanpain graduated as a Medical Doctor (MD) and is board certified in internal medicine from the Université Libre de Bruxelles, Belgium. He performed his PhD in he laboratory of Marc Parmentier, where he studied how CCR5 interacts with its natural ligands and the HIV envelope to mediate viral entry. He started his career in stem cell (SC) biology as a postdoctoral fellow in the laboratory of Elaine Fuchs, Rockefeller University, where he developed new methods to isolate and characterize hair follicle SC and study the mechanisms regulating their function.

Cédric Blanpain started his own lab at the Université Libre de Bruxelles in October 2006 where he is now full professor, WELBIO investigator and director of the laboratory of stem cells and cancer. His research group uses lineage-tracing approaches to study the role of SCs during development, homeostasis and cancer. His group uncovered the existence of stem cells and progenitors acting during homeostasis and repair of the epidermis and uncovered a novel paradigm of lineage segregation in the mammary gland and prostate. His lab was pioneered in using mouse genetics to lineage trace the origin of epithelial cancers. They identified the cancer cell of origin and the mechanisms regulating the early steps of tumor initiation in skin basal cell carcinoma, skin squamous cell carcinoma and PIK3CA mediated mammary tumors. His lab developed novel approaches to unravel the mode of tumour growth within their natural environment and to understand the mechanisms that regulating cancer stem cell functions.

Cedric Blanpain received several prestigious and highly competitive awards including EMBO Young investigator award, ERC starting and ERC consolidator grants, the outstanding young investigator award of the ISSCR 2012, the Liliane Bettencourt award for life sciences 2012, Joseph Maisin Award for basic biomedical Science 2015. He has been elected member of the EMBO in 2012, the Belgian Royal Academy of Medicine, and the Academia Europa. He is member of the advisory board of several leading research institutes across Europe. He is member of the editorial board of The EMBO Journal, The Journal of Cell Biology, Cell Reports, Stem Cell Reports, Stem Cells and Development.

Michael Boutros is the head of the Division Signaling and Functional Genomics and Speaker of the Functional and Structural Genomics Program at the German Cancer Research Center (DKFZ). He is also Professor for Cell and Molecular Biology at Heidelberg University. After his PhD with Marek Mlodzik at the European Molecular Biology Laboratory (EMBL), he joined the laboratory of Norbert Perrimon at Harvard Medical School as a postdoctoral fellow. In 2003, he started his independent group at the DKFZ in Heidelberg funded by an Emmy-Noether Grant of the German Research Foundation. He was also supported by the EMBO Young Investigator Program. He later became head of Division and full Professor at Heidelberg University. Michael Boutros’ research interests include functional genomic approaches to understand the regulation of cellular signaling in normal and cancer cells. His laboratory further develops and applies high-throughput screening methodologies to dissect genetic networks and genotype-specific vulnerabilities. His is supported by the European Research Council (ERC) and is an elected member of the European Molecular Biology Organisation (EMBO). 

Nils Brünner

Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark

E-mail: nbr@sund.ku.dk

Professor Nils Brünner, DMSc, MD, received his basic medical education at University of Copenhagen, Denmark. He then trained in internal medicine and medical oncology at hospitals in Greater Copenhagen. In 1987, he went to the National Cancer Institute, NIH, Maryland, USA for one year and then to Lombardi Cancer Research Centre, Georgetown University Hospital, Washington DC for a second year. He received his education in molecular and cellular biology during these two years abroad. Back in Denmark he joined the Finsen Laboratory, Rigshospitalet in Copenhagen, where until 2002, he was leading a research group working with translational cancer research within proteinases, their receptors and inhibitors. In 2002 he became full Professor at the Faculty of Life Sciences, University of Copenhagen. He is currently leading a research group mainly focusing on non- anti-proteolytic functions of protease inhibitors. He is author of more than 250 publications, many of which deal with translational research on proteinase inhibitors and breast cancer or colorectal cancer. Nils Brünner has a long-standing membership of the EORTC Pathobiology Group, and he served as Chairman of Laboratory Research Division and member of the Executive Board of EORTC 2003-2006.

  • Carlos Caldas
  • Carlos Caldas

    Professor of Cancer Medicine, University of Cambridge
    Senior Group Leader, Cancer Research UK Cambridge Institute
    NIHR Senior Investigator
    Director, Cambridge Breast Cancer Research Unit
    Honorary Consultant Medical Oncologist, Addenbrooke’s Hospital

    E-mail: carlos.caldas@cruk.cam.ac.uk

Professor Caldas holds the Chair of Cancer Medicine at the University of Cambridge since 2002. He is an Honorary Consultant Medical Oncologist at Addenbrooke’s Hospital, Lead of the Cambridge Experimental Cancer Medicine Centre, Co-Lead of the Cancer Theme at the NIHR Cambridge BRC and Director of the Cambridge Breast Cancer Research Unit. He heads the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Institute. He is Fellow of the American College of Physicians, the Royal College of Physicians, the Royal College of Pathologists and the Society of Biology. He was elected a Fellow of the Academy of the Medical Sciences in 2004 and a Fellow of the European Academy of Cancer Sciences in 2010. He was selected as an NIHR Senior Investigator in 2012.

Professor Carlos Caldas is a graduate from the University of Lisbon Medical School and trained in Internal Medicine at UT Southwestern, Dallas and in Medical Oncology at Johns Hopkins Hospital, Baltimore. He then completed a research fellowship at the Institute of Cancer Research in London. In 1996 he moved to Cambridge where he has directed a research group working on the genetic alterations underlying human epithelial malignancies, with a particular focus on breast cancer.

His current research focus is in the functional genomics of breast cancer and its biological and clinical implications. He has also a research program on the genetics of gastric cancer. His main clinical interest is in breast cancer and novel molecularly targeted therapies. He has published over 200 peer-reviewed papers including in Nature, Nature Genetics, Nature Medicine, Cell, Cancer Cell, Cell Reports, New England Journal of Medicine, Science Translational Medicine, PNAS, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Genome Biology, PLoS Biology, PLoS Medicine, Lancet Oncology, Journal of Pathology, Breast Cancer Research and Oncogene.

  • George Adrian Calin. MD, PhD

George Adrian Calin received both his M.D. and Ph.D. degrees at Carol Davila University of Medicine in Bucharest, Romania. After working cytogenetics as undergraduate student with Dr. Dragos Stefanescu in Bucharest, he completed a cancer genomics training in Dr. Massimo Negrini’s laboratory at University of Ferrara, Italy. In 2000 he became a postdoctoral fellow at Kimmel Cancer Center in Philadelphia, PA, and while working in Dr. Carlo Croce laboratory Dr. Calin was the first to discover the link between microRNAs and human cancers, a finding considered as a milestone in microRNA research history. He is presently a Professor in Experimental Therapeutics and Leukemia Departments at M. D. Anderson Cancer Center in Houston and studies the roles of microRNAs and other non-coding RNAs in cancer initiation and progression and in immune disorders, as well as the mechanisms of cancer predisposition linked to non-codingRNAs. Furthermore, he explores the roles of body fluids miRNAs as potential hormones and biomarkers, as well as new RNA therapeutic options for cancer patients. Simply, he is having fun making discoveries and publishing and, from time to time, getting funded grants!

  • Carlo M. Croce

    The John W. Wolfe Chair in Human Cancer Genetics; Chairman, Department of Molecular Virology, Immunology and Medical Genetics; Director, Human Cancer Genetics Program; Director, Genetics Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    E-mail: carlo.croce@osumc.edu

An excellent researcher whose work has revealed the variety of mutated genes involved in leukemias, lymphomas and other cancers, Carlo M. Croce, M.D., Director of Human Cancer Genetics, Chairman of Molecular Virology, Immunology and Medical Genetics, and Director of the Institute of Genetics at The Ohio State University Comprehensive Cancer Center, has been awarded the 30th Annual Jeffrey A. Gottlieb Memorial Award. Dr. Croce is world-renowned for his contributions involving the genes and genetic mechanisms implicated in the pathogenesis of human cancer. During the course of his career, he discovered the juxtaposition of the human immunoglobulin genes to the MYC oncogene, the deregulation of MYC in Burkitt lymphoma, the ALL1 gene involved in acute leukemias, the TCL1 gene associated with T-cell leukemias, and cloned and characterized the BCL2 gene involved in follicular lymphoma. Dr. Croce has also uncovered the early events involved in the pathogenesis of lung, nasopharyngeal, head and neck, esophageal, gastrointestinal and breast cancers. His discoveries have led to revolutionary innovations in the development of novel and successful approaches to cancer prevention, diagnosis, monitoring and treatment, based on gene-target discovery, verification and rational drug development. A native of Milan, Italy, Dr. Croce earned his medical degree, summa cum laude, in 1969 from the School of Medicine, University of Rome. He began his career in the United States the following year as an associate scientist at the Wistar Institute of Biology and Anatomy in Philadelphia. In 1980, he was named Wistar Professor of Genetics at the University of Pennsylvania and associate director of the Wistar Institute, titles he held until 1988. From 1988 to 1991, he was director of the Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine in Philadelphia. In 1991, Dr. Croce was named Director of the Kimmel Cancer Center at Jefferson Medical College at the Thomas Jefferson University, in Philadelphia. Under his direction at Ohio State faculty within the Human Cancer Genetics Program conduct both clinical and basic research. Basic research projects focus on how genes are activated and inactivated, how cell-growth signals are transmitted and regulated within cells, and how cells interact with the immune system. Clinical research focuses on discovering genes linked to cancer and mutations that predispose people to cancer. Dr. Croce, a member of the National Academy of Sciences in the US and the Accademia Nazionale delle Scienze detta deiXL in Italy, has received almost every significant award for cancer research that one can earn. He was awarded two Outstanding Investigator awards from the National Cancer Institute, the Richard and Hinda Rosenthal Foundation Award and the G.H.A. Clowes Memorial Award from the American Association for Cancer Research, the John Scott Award, the Robert J. and Claire Pasarow Foundation Cancer Award, the GM Cancer Research Foundation – Charles S. Mott Prize, the Scanno Prize for Medicine, the AACR-Pezcoller Award, the Raymond Bourgine Award and Gold Medal of Paris and President of the Republic Prize, the iwCLL Binet-Rai-Medal for Outstanding Contribution to CLL Research, the Henry M. Stratton Medal from the American Society of Hematology, the Albert Szent-Györgyi Prize for Progress in Cancer Research, the 2008 Leopold Griffuel Prize awarded by the French Association for Cancer Research, The Ernst W. Bertner Memorial Award, The University of Texas M.D. Anderson Cancer Center and most recently, an Elected Member of The American Academy of Arts and Sciences. He is principal investigator on seven federal research grants and has more than 875 peer-reviewed, published research papers.

Eleftherios P. Diamandis is currently Professor and Head, Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology, University of Toronto and Head, Section of Clinical Biochemistry, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto.

Dr Diamandis received his B.Sc. in Chemistry, Ph.D. in Analytical Chemistry and M.D. from the University of Athens, Greece and his Diploma in Clinical Biochemistry from the University of Toronto, Canada. He is a Certified Clinical Chemist by the Canadian Academy of Clinical Biochemistry and the American Board of Clinical Chemistry.

He has published 4 books, 50 review papers and over 350 research papers. His interest is in tumor markers, genomic and proteomic technologies and their applications to diagnosis and monitoring of cancer.

Dr Pier Paolo Di Fiore received his M.D./Ph.D from the University of Naples Italy and was subsequently Board certified in Oncology, at the same University. After finishing a Fogarty Fellowship at the National Cancer Institute, NIH, he was tenured and served as Section Chief in the Laboratory of Molecular and Cellular Biology of the NCI. In 1995, he returned to Italy; he is now the Scientific Director of the FIRC Institute for Molecular Oncology Foundation in Milan and Professor of General Pathology at the University of Milan. His research interests include studies on the mechanisms of signal transduction by growth factor receptors in tumours and the role of endocytosis in this process. He is a member of the European Molecular Biology Organization (EMBO) and Editor of The Journal of Cell Biology. He has published more than 150 papers in international journals. In the course of his career, he has received significant honors and awards, such as the Swiss Bridge Award and the Technology Transfer Award of the National Cancer Institute (NIH), and has pioneered the development of two biotech companies.

Lee M. Ellis, MD, completed his residency in surgery at the University of Florida in 1990. Dr Ellis went on to complete a surgical oncology fellowship at the M.D. Anderson Cancer Center, where he has been on the faculty since 1993. He has a dual appointment as a Professor in the departments of Surgical Oncology, and Molecular and Cellular Oncology.

Dr Ellis has a clinical practice in Surgical Oncology, where he operates on patients with colorectal cancer and liver metastases. Academically, Dr Ellis has established a reputation for expertise in the area of angiogenesis and growth factor receptors in gastrointestinal malignancies. His group was the first to demonstrate that VEGF was a valid target in colorectal cancer. He has been a consultant to numerous branches of the NCI including CTEP. In 2000, he was awarded the Faculty Scholar Award from the MD Anderson Cancer Center and in 2007 The William C. Liedtke, Jr, Chair in Cancer Research.

Dr Ellis serves on 8 editorial boards, including the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, and Molecular Oncology and has authored over 220 peer-reviewed publications, 100 invited reviews and editorials, three books, and 30 book chapters. He has served as a bridge in translating research between the laboratory and the clinic. Dr. Ellis has published several important editorials in journals such as the Nature, NEJM, Cell, Cancer Cell, Nature Medicine, JNCI, JCO, Nature Drug Discovery, and The Lancet. He is co-chair of the largest clinical angiogenesis meeting in the world held in Jan/Feb annually. In May 2013, Dr Ellis assume the position of Vice Chair of Translational Medicine, SWOG. He also serves a lead role in ASCO and the AACR. Most recently, he served as Chair of ASCO's Cancer Research Committee, and is currently on the Nominating Committee of ASCO. He was co-director of the "Vail Course"-AACR/ASCO Workshop: Methods in Clinical Research from 2010-2012. Dr. Ellis currently serves is Vice-Chair of the NCI Colon Cancer Task Force and Initiated and Leads The Innovation Working Group of the NCI GI Cancers Steering Committee. He is a consultant to numerous Pharmaceutical and Biotechnology companies involved in targeted therapies.

  • Manel Esteller

    Director Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO), Barcelona, Spain

    E-mail: mesteller@idibell.cat

Dr Esteller graduated in Medicine with Honors from the University of Barcelona, Catalonia, Spain and obtained his PhD Degree Cum Laude at the University of Barcelona. He was an Invited Researcher at the University of St. Andrews, Scotland, United Kingdom and a Postdoctoral Researcher and Research Associate at The Johns Hopkins University and School of Medicine, Baltimore, USA. Author of more than 160 original peer-reviewed manuscripts in biomedical sciences in the most highly-ranked journals, he has placed the hypermethylation-associated silencing of tumor suppressor genes and the landscape of histone modifications at the forefront, not only of epigenetics, but also of the current cancer research. He is an advisor and advocate of the Human Epigenome Project and Associate Member of the European Network of Excellence the Epigenome. His numerous awards include: Best Young Investigator from the European Association for Cancer Research (2000), Hospital de Madrid Foundation Award for Translational Science (2005), Beckman-Coulter Award from the Spanish Association of Biochemistry and Molecular Biology (2006), Biomedical Research Award Francisco Cobos Foundation (2006), Oxford University Press Carcinogenesis Award (2006) and Swiss Bridge Cancer Award (2006).

1975: B.A. Indiana University, Bloomington, IN (Philosophy)
1979: Ph.D. Indiana University, Bloomington, IN (Chemistry)
1981: M.D. Indiana University School of Medicine, Indianapolis, IN

Academic Appointments:
1987-1988: Instructor in Pediatrics, Harvard Medical School, Boston, MA
1988-1993: Assistant Professor of Pediatrics, Harvard Medical School, The Children's Hospital, Boston, MA
1990-1995: Faculty Member, Cell and Developmental Biology Program, Harvard Medical School, Boston, MA
1993-1995: Associate Professor of Medicine, Massachusetts General Hospital, Boston, MA
1994-1995: Sabbatical: Visiting Scientist, Fred Hutchinson Cancer Research Center, Seattle, WA
1995-1998: Professor, Department of Pathology, University of Washington, Seattle, WA
1995-2000: Full Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
1997-1999: President and CSO of Rosetta Inpharmatics, Inc., Kirkland, WA
2000-2001: President and CEO of Rosetta Inpharmatics, Inc., Kirkland, WA
2001-present: President, Rosetta Inpharmatics, LLC, Seattle, WA
2001-2002: Vice President, Basic Research, Merck Research Laboratories, Merck & Co., Inc., West Point, PA
2002-2003: Vice President, Molecular Profiling, Merck Research Laboratories, Merck & Co., Inc., West Point, PA
2003-2004: Senior Vice President, Molecular Profiling & Basic Cancer Research, Merck Research Laboratories, Merck & Co., Inc., West Point, PA
2004-2005: Senior Vice President, Molecular Profiling & Cancer Research, Merck Research Laboratories, Merck & Co., Inc., West Point, PA
2004-present: President, Aton Pharma, Inc.
2005-present: Executive Vice President, Oncology, Merck Research Laboratories, Merck & Co., Inc., North Wales, PA

Hospital Appointments:
1988: Assistant Pediatrician, Children's Medical Center and Massachusetts General Hospital, Boston, MA
1989-1990: Assistant Member, MGH Cancer Center, Massachusetts General Hospital, Boston, MA
1990-1991: Associate Member, MGH Cancer Center, Massachusetts General Hospital, Boston, MA
1991-1995: Member, MGH Cancer Center, Massachusetts General Hospital, Boston, MA

Awards and Honors:
Recent awards and honors include:
1993: American Cancer Society Faculty Research Award
1994: Robert Steel Visiting Professor, Memorial Sloan-Kettering
1995: J.W. Meakin Prize in Oncology, Ontario Cancer Treatment and Research Foundation

Major Research Interests:
1. Clinical Applications of Checkpoint Controls
2. Molecular Biology of Embryonal Tumors
3. Tumor Suppressor Genes
4. Molecular Pharmacology
5. Array Technology
6. Genomic Approaches to Drug Discovery

Dr Friend is also author of 69 original articles and 33 chapters, reviews and editorials.

Todd Golub is a founding member of the Broad Institute of Harvard and MIT and serves as director of its Cancer program. Todd is a world leader in applying genomic tools to the classification and study of cancers. His work focuses on using the human genome to understand the biological and clinical challenges facing cancer medicine. He has made fundamental discoveries in the molecular basis of childhood leukaemia, and pioneered the use of genomic approaches, particularly DNA microarrays, to cancer biology. Todd is the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute, associate professor of pediatrics at Harvard Medical School, and an investigator at Howard Hughes Medical Institute. Todd is the recipient of multiple awards, including Discover Magazine's Inventor of the Year (Health Category) in 2000, the Daland Prize of the American Philosophical Society in 2001, and the Outstanding Achievement Award (formerly Cornelius Rhoads Memorial Prize), American Association for Cancer Research in 2002.

Todd received his BA in 1985 from Carleton College and his MD in 1989 from the University of Chicago Pritzker School of Medicine.

H. Barton Grossman holds the W. A. "Tex" and Deborah Moncrief, Jr. Distinguished Chair in Urology at The University of Texas M. D. Anderson Cancer Center. He is a Professor in the Departments of Urology and Cancer Biology and Deputy Chairman of the Department of Urology at M. D. Anderson. He has had a long-standing clinical and basic research interest in bladder cancer. He is currently Co-PI of the M. D. Anderson SPORE focused on bladder cancer and a member of the Program for the Assessment of Clinical Cancer Tests (PACCT) Strategy Group of the National Cancer Institute. He is on the editorial boards of Journal of Urology, Urologic Oncology, and Oncology Reports. He is a reviewer for multiple journals and has over 200 peer-reviewed publications.

Nadia Harbeck is Associate Professor in the Department of Obstetrics and Gynaecology, Technical University of Munich, Munich, Germany, where she is responsible for breast cancer systemic therapy (including trials) and coordinating clinical and translational breast cancer research. Professor Harbeck is a member of the German AGO breast cancer guideline committee, a steering committee member of the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology Group, the Breast Cancer Group of the Munich Tumor Center, TransBIG, TransHERA, and a member of numerous other professional organisations, including the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). She is also the Principal Investigator and steering committee member of several national and international clinical breast cancer trials. Professor Harbeck has authored more than 140 papers in peer-reviewed journals with her research focus being on prognostic and predictive factors in breast cancer and other solid malignancies. She has received numerous awards for her translational research, including the 2001 ASCO Fellowship Merit Award, a 2001 AACR Award for clinical-translational research, and the 2002 AGO Schmidt-Matthiesen Award for Gynecological Oncology. She was recently elected to give the Emmanuel van der Schueren Invited Lecture in the opening ceremony at EBCC 6 (Berlin, Germany, April 2008).

  • Daniel F. Hayes

    Professor of Internal Medicine, University of Michigan and Director, Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA

    Website: http://www.med.umich.edu/
    E-mail: hayesdf@umich.edu

Dr Daniel Hayes has a long history of involvement in laboratory, translational, and clinical research in breast cancer, particularly in tumor marker development and evaluation and novel therapy development. He has served as the Vice Chair of the Breast Committee of the Cancer and Leukemia Group B, and chaired the Solid Tumor Correlative Sciences Committee of the CALGB, from 1996-2001. He now holds a similar position in the Southwest Oncology Group, and he chairs the U.S. Breast Cancer Intergroup Correlative Sciences Committee.

Dr. Hayes has or is serving on the Editorial Boards of several scientific journals, including the Journal of Clinical Oncology, Clinical Cancer Research, Breast Cancer Research and Treatment, The Breast Journal, Clinical Breast Cancer, and Breast Cancer Research. Dr. Hayes has served on several prestigious committees, including the recently convened Institute of Medicine Committee which authored the report "Mammography and Beyond," and he co-chairs the Tumor Marker Expert Advisory Panel for the American Society of Clinical Oncology. This considerable experience in designing, performing, and evaluating clinical trials in breast cancer are particularly important for his role in this grant, as a consultant, advisor and co-investigator for studies of patient oriented decision aids.

  • Carl-Henrik Heldin

    Branch Director, Ludwig Institute for Cancer Research, Uppsala, Sweden
    Professor in Molecular Cell Biology, Uppsala University, Sweden

    E-mail: C-H.Heldin@LICR.uu.se

C. H. Heldin has been the Branch Director of the Ludwig Institute for Cancer Research in Uppsala, Sweden since 1986, and from 1992 also professor in Molecular Cell Biology at Uppsala University. He was born in 1952, and obtained a PhD degree in Medical and Physiological Chemistry in 1980 at the University of Uppsala, where he continued to work until 1985, in a position sponsored by the Swedish Cancer Society.

The research interest of C. H. Heldin is related to the mechanisms of signal transduction by growth regulatory factors, as well as their normal function and role in disease. In particular, platelet-derived growth factor (PDGF), a major mitogen for connective tissue cells, and transforming growth factor-? (TGF-?), which inhibits the growth of most cell types, are studied. An important goal is to explore the possible clinical utility of signal transduction antagonists.

C. H. Heldin is a member of the European Molecular Biology Organization, the Royal Swedish Academy of Sciences and Academia Europea. He serves or has served on the Scientific Advisory Boards of several companies and academic institutions, including the German cancer Center, Heidelberg, Max-Planck-Institute for Biochemistry, Martinsried, European Institute for Oncology, Milan, and European Molecular Biology Laboratory, Heidelberg. C. H. Heldin is currently on the Board of the European Research Council and the Swedish Research Council, and serves as Senior Editor for Cancer Research and Associate Editor for Molecular Biology of the Cell, Genes to Cells and Growth Factors.

C. H. Heldin has published more than 340 research articles and 170 reviews, and has received several scientific awards, including Prix Antoine Lacassagne (1989), K. Fernströms Large medical Prize (1993) and the Pezcoller-American Association for Cancer Research Award (2002).

Thomas Helleday

SciLife Laboratory, Karolinska Institutet, Stockholm, Sweden

E-mail: Thomas.helleday@scilifelab.se

Professor Thomas Helleday is the Torsten and Ragnar Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden.

Thomas Helleday obtained his first degree in molecular biology at the Stockholm University (1995). Alongside these studies, he took a degree in Business Administration and Economics at the same university (1996). In 1999, he was awarded a PhD from Stockholm University for his studies on homologous recombination in mammalian cells. 

After a short post-doctoral research period at the Institute for Cancer Research, Sheffield, UK, he obtained a lectureship at the same institute and set up his own group. At the same time, he maintained grants and a position at the Stockholm University, allowing his group to continue research at the Department of Genetics, Microbiology and Toxicology. Thomas Helleday held two professorships; one as MRC Professor of Cancer Therapeutics at the Gray Institute for Radiation Oncology and Biology at the University of Oxford, and the other as Professor of Molecular Genetics at the Department of Genetics, Microbiology and Toxicology at Stockholm University.

Currently Professor Helleday heads a large multidisciplinary translational research group focusing on understanding basic DNA repair and DNA-damage and developing novel drugs for anti-cancer treatments. The group was first to demonstrate a novel concept for treating cancer called “synthetic lethality” established by the selective killing of BRCA1 or BRCA2 mutated breast and ovarian cancers by PARP inhibitors (now EMA/FDA approved). The research covers both basic and translational work including academic-driven clinical trials, based on basic science findings in his laboratory.

  • Manuel Hidalgo
  • Manuel Hidalgo

    Vicedirector of Translational Research, Clinical Research Programme Director and Head of Gastrointestinal Cancer Clinical Research Unit at the SPANISH NATIONAL CANCER RESEARCH CENTRE (CNIO)
    Beth Deaconness Medical Center, Harvard Medical School, Boston, USA

    E-mail: mhidalgo@bidmc.harvard.edu

Manuel Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997.

Manuel specialised in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programmes.

He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the pancreatic cancer research team - a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus - two recently approved drugs.

Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilisation of personalised xenograft models for drug screening, biomarker development and personalised cancer treatment.

He has published 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO.

Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. In 2011, he was named Vice Director of Translational Research at CNIO charged with the mission to foster translational research at CNIO and with a broader implication of the Center in cancer care.

Hedvig Hricak is Chairman of the Department of Radiology at Memorial Sloan-Kettering Cancer Center. She holds a senior position within the Program of Molecular and Pharmacology Therapeutics at the Sloan-Kettering Institute, is a Professor at Gerstner Sloan-Kettering Graduate School of Biomedical Sciences and is a Professor of Radiology at the Weill Medical College of Cornell University. She earned her MD degree from the University of Zagreb and her Dr. Med. Sc. from the Karolinska Institute. In 2005 she was awarded an honorary doctorate in medicine (Dr.h.c.) from Ludwig Maximilian University in Munich, Germany. Prior to joining MSKCC, she was a professor of radiology, radiation oncology, urology and gynecology at the University of California, San Francisco and was the chief of the abdominal section of the Department of Radiology at the UCSF Medical Center. She has helped develop applications in ultrasound, MR, and CT for gynecological cancers as well as MR and MR spectroscopy for prostate cancer. She continues to investigate diagnostic methods for cancer detection, staging, and management and is involved in developing clinical approaches for molecular imaging of cancer.

Dr. Hricak is a member of the Institute of Medicine (IOM) of the National Academies of Science. She serves as a member of the Nuclear Radiation Study Board of the National Academies. She is also a "foreign" member of the Croatian Academy of Arts and Sciences. Dr. Hricak serves on the committees or executive boards for a number of medical societies and served as President of the California Academy of Medicine (1999), President of the Society for the Advancement of Women's Imaging (1997–1999), President of the Society of Uroradiology (2000–2003), and President of the New York Roentgen Society (2004–2005) and President of the Radiological Society of North America (2009–2010).

Dr. Hricak has authored or co-authored 342 peer-reviewed original research articles, 159 review/editorial articles, 133 book chapters. She has given more than 130 named or keynote lectures and has been a visiting professor at more than 30 institutions worldwide. She has had multiple government sponsored grants throughout her career and is currently the PI on 3 NIH funded awards. She is a fellow of the American College of Radiology, the International Society for Magnetic Resonance in Medicine, and the Society of Uroradiology. In recognition of her career accomplishments, she has received the Marie Curie Award of the American Association of Women Radiologists, the gold medals of the International Society for Magnetic Resonance in Medicine and the Association of University Radiologists, the Bé clère medal of the International Society of Radiology, the Morocco Medal of Merit, and the Katarina Zrinska Croatian presidential award. She is an honorary fellow of the Royal College of Radiologists and an honorary member of the British Institute of Radiology, German Radiological Society, Austrian Roentgen Society, Croatian Society of Radiology, Journé es Françaises de Radiologie, Swedish Society of Medical Radiology, Chinese Radiological Society, Japanese Radiological Society, Israel Radiological Association and Indian Radiological and Imaging Association.

Tony Hunter is an American Cancer Society Research Professor and Director of the Molecular and Cell Biology Laboratory at the Salk Institute for Biological Studies in La Jolla, California. He is also an Adjunct Professor in the Division of Biological Sciences at the University of California at San Diego. He is best known for his discovery of tyrosine phosphorylation, and the elucidation of its role in cell proliferation and malignant transformation. His general area of interest is in understanding mechanisms of signal transduction that utilize protein phosphorylation, ubiquitination and sumoylation and are involved in cell proliferation and growth control, and in cell cycle checkpoint activation in response to DNA damage.

Johanna Ivaska

University of Turku, Turku Centre for Biotechnology

E-mail: joivaska@utu.fi

Johanna Ivaska is a Professor of Molecular Cell Biology at University of Turku in Finland. She is currently also Academy Professor and was nominated EMBO member 2015. After obtaining her PhD at the University of Turku she did a post-doc in the laboratory of Peter Parker in CR-UK London Research Institute. She moved to VTT technical Research Centre of Finland to establish her research group “Cell adhesion and cancer” in 2003 and in 2013 moved to her current position in University of Turku Centre for Biotechnology. Her research main research interests relate to the biological role of integrins in cancer progression. The current main research focus is integrin mediated cell adhesion and migration, cell-matrix interactions and mechanosensing as well as molecular mechanisms governing endosomal traffic of integrins and growth factor receptors in cancer.

Dr Jaffe received an M.D. from the University of Pennsylvania. She trained in pathology at the NCI. In 1980 she became Chief, Hematopathology Section, and is currently Acting Chief of pathology.

Her clinical and investigational studies are intertwined to alter and enhance our understanding of the malignant lymphomas. One of her earliest papers on follicular lymphoma (1974), a Citation Classic, presented evidence for the origin of this tumor from follicular B cells. More recently she described in situ follicular lymphomas, which provide insight into the earliest events of follicular lymphomagenesis. Her work stresses the clinical implications of diagnoses, emphasizing the role as pathologists as clinical consultants.

Science Watch named her among the 10 most highly cited researchers in clinical oncology from 1981 and 1998. Dr. Jaffe has been president of both the Society for Hematopathology as well as the United States and Canadian Academy of Pathology. She has held several positions in the American Society of Hematology. In 1993, she was elected a fellow of the American Association for the Advancement of Science, and subsequently was elected Chair of the Medical Sciences Section of AAAS. Among her awards are the Fred W. Stewart Award from Memorial-Sloan Kettering Cancer Center, and the Lennert prize from the European Association for Haematopathology. She has served on 12 journal editorial boards, including The American Journal of Pathology, The American Journal of Surgical Pathology, Blood, Cancer Research, and Modern Pathology, among others

Dr. Jaffe was a member of the Steering Committee and Senior Editor for the (2001) WHO Classifications of Tumors: Pathology and Genetics of the Hematopoietic and Lymphoid Tissues, and is currently serving on the Steering Committee for the next edition in preparation. She also has been named one of the four Series Editors for the entire WHO monograph series on the Pathology and Genetics of Tumours.

  • Olli Kallioniemi

    Professor of the Academy of Finland, Director, Centre of Excellence in Translational Genome-Scale Biology, Medical Biotechnology VTT Technical Research Centre of Finland and University of Turku Finland

    Website: http://www.vtt.fi
    E-mail: Olli.Kallioniemi@helsinki.fi

Dr. Kallioniemi received his MD in 1984 and PhD in 1988 at the University of Tampere in Finland. Board certification in Laboratory Medicine in 1990. Visiting fellow at UC San Francisco 1990-1992. Senior Scientist and Professor of Cancer Biology at the University of Tampere 1993-1995. Principal Investigator and Head of Translational Genomics Section (1995-2002) at the Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, NIH, Maryland, Professor of Medical Biotechnology at the VTT Technical Research Centre of Finland and the University of Turku, Finland (2003-present), with Academy of Finland Professorship for 2004-2008.

Author of 208 publications. Invited lecturer in over 114 meetings in the past 5 years. Editor or member of the editorial board of six journals. Inventor of 15 issued patents, with a focus on technology development. Dr. Kallioniemi has played a key role in the development of Comparative Genomic Hybridization (CGH) technique in 1992, tissue microarray (TMA) technology in 1998 and RNAi microarrays in 2001 and NMD microarrays in 2004. EACR young investigator award in 1994, Anders Jahre Young Scientist Prize in 1998, NIH Director's Lecture in 2000, Medal of the Swedish Medical Society 2002, Member of the Academy of Finland (2005), EMBO-member (2006).

Olli Kallioniemi's current research focuses on "Canceromics" and "Cancer-Systems Biology" research with a focus on the identification of therapeutic targets, pathways and leads as well as mechanisms of action of cancer drugs.

  • Guido Kroemer

    Dr. Director
    Institut de Cancé rologie Gustave Roussy, Villejuif, France

    E-mail: kromer@orange.fr

Guido Kroemer is Professor at the Faculty of Medicine, University Paris Descartes; Director of Unit 848 INSERM "Apoptosis, Cancer & Immunity"; and Director of the Metabolomics Platform at the Institut Gustave Roussy.

Guido Kroemer got his M.D. in 1985 from the University of Innsbruck, Austria, and his Ph.D. in molecular biology in 1992 from the Autonomous University of Madrid, Spain. Since then he has worked as a research director at the French Medical Research Council (INSERM) in Villejuif. Since 2010 he is professor at University of Paris Descartes. He has made important contributions to medical research through his groundbreaking work in the fields of cell biology and cancer research. He is best known for the discovery that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death. Prof. Kroemer has explored the fine mechanisms of mitochondrial cell death control, the molecular pathways that explain the inhibition of cell death in cancer cells, upstream of or at the level of mitochondria, and the mechanisms that make cancer cell death immunogenic. His work has had far reaching implications for the comprehension, detection and therapeutic manipulation of cellular demise. His contributions have been recognized with numerous awards, including the prestigious Descartes Prize of the European Union, the Carus Medal of the German Academy of Sciences, the Grand Prix Mergier-Bourdeix of the French Academy of Sciences, the Lucien Dautrebande Prize of the Belgian Royal Academy of Medicine, the Gallet & Breton Prize of the French Academy of Medicine and many others. He currently serves on more than forty editorial boards. These include EMBO Journal, EMBO Reports, Cancer Research, Oncogene and Cell Death & Differentiation. Prof. Kroemer is also the Editor-in-Chief of Cell Death & Disease. A prolific scholar, he has more than 550 scientific publications with about 50,000 citations. He is currently the most cited scientist worldwide in the field of cell death as well as in the area of mitochondrial research. He has delivered numerous keynote addresses at symposia internationally. He is member of EMBO, German Academy of Sciences (Leopoldina), Academia Europaea, European Academy of Sciences (EAS) and European Academy of Sciences and Arts (EASA). He is the President elect of the European Cell Death Organization (ECDO) and the Founding Director of the European Research Institute for Integrated Cellular Pathology (ERI-ICP).

  • Ole Christian Lingjaerde
  • Ole Christian Lingjærde

    Professor of Computer Science (Informatics)
    Head of Biomedical Research Group, Department of Informatics, University of Oslo
    Principal investigator, Centre for Cancer Biomedicine, Oslo University Hospital/University of Oslo

    E-mail: ole@ifi.uio.no

  • Edison T. Liu

    Executive Director, Genome Institute of Singapore (Biomedical Sciences Institutes)
    Professor of Medicine, National University of Singapore
    Special Advisor to the President, National University of Singapore
    Director, Singapore Cancer Syndicate
    Director, Singapore Tissue Network

    Website: http://www.gis.a-star.edu.sg/internet/site/
    E-mail: edison.liu@jax.org

Dr. Edison Liu was born in Hong Kong, China and received his bachelor's degree (Phi Beta Kappa) in chemistry and psychology from Stanford University where he remained to complete his M.D. in 1978. This was followed by internship and residency in internal medicine at Washington University, St. Louis, and clinical cancer fellowships at Stanford University (Oncology), and at the University of California at San Francisco (Hematology). He then pursued post-doctoral studies as a Damon-Runyan Cancer Research Fellow at the University of California at San Francisco in the laboratory of Dr. J. Michael Bishop. In 1987 when he joined the faculty of Medicine at the University of North Carolina at Chapel Hill. At UNC, Dr. Liu held faculty appointments in medicine, biochemistry, epidemiology, and genetics, and was director of UNC's Specialized Program of Research Excellence (SPORE) in Breast Cancer. Dr. Liu was leader of the Breast Cancer Program at the Lineberger Comprehensive Cancer Center, and co-founder of the Breast Care Center at UNC. In 1995, he was appointed Chief of the Division of Medical Genetics, School of Medicine, UNC. In 1996, he joined the NCI as the Director of the Division of Clinical Sciences. In this capacity, he was responsible for the scientific and administrative direction for the intramural clinical research arm of the NCI comprised of over 100 principal investigators, 400 trainees, and 1,200 employees.

In 2001, Dr. Liu assumed the position of Executive Director, Genome Institute of Singapore which is a key programme of the Biomedical Sciences Initiative of Singapore. The GIS now houses 230 individuals focused on integrating genomic sciences with cell and medical biology using systems approaches. His current scientific research investigates the dynamics of gene regulation on a genome scale that can explain biological states in cancer. Dr. Liu has contributed over 200 articles, reviews, and book chapters to the scientific literature. Dr. Liu also is the executive director of the Singapore Cancer Syndicate, a governmental funding agency supporting clinical translational cancer research, and the Managing Director of the Singapore Tissue Network, the national tissue repository in Singapore.

Dr. Liu has received a number of awards including the Leukemia Society Scholar (1991-1996), the Brinker International Award for basic science research in Breast Cancer (1996), the Rosenthal Award from the American Association for Cancer Research for his work in elucidating the importance of the HER-2 gene as a predictive marker for breast cancer adjuvant therapy (2000). Dr. Liu was recently the recipient of the President's Public Service Medal for his work in helping Singapore resolve the SARS crisis.

  • Chris Lord
  • Chris Lord

    Team Leader of the CRUK Gene Function Laboratory and Reader in Cancer Genomics and Therapeutics in the Breast Cancer Now Research Centre at the Institute of Cancer Research, London

    Website: http://www.icr.ac.uk/
    E-mail: Chris.Lord@icr.ac.uk

Dr Chris Lord is Team Leader of the CRUK Gene Function Laboratory and Reader in Cancer Genomics and Therapeutics in the Breast Cancer Now Research Centre at the Institute of Cancer Research, London. Much of the focus of his work is in exploiting genetic concepts such as synthetic lethality and functional genomics approaches to understand the behaviour of tumour cells. The ultimate aim of this work is to use this information to design novel ways to treat the disease. In recent years Dr Lord’s Gene Function Team at the ICR have used these approaches to understand how PARP inhibitors might be used to treat cancer and to develop novel drugs. In addition, the laboratory has focussed on identifying and validating novel targets for use in breast cancer as well as dissecting the genetic control of drug sensitivity and drug resistance in this disease. Dr Lord studied Biochemistry at the University of Surrey and completed his DPhil in 1997, working on complex disease genetics at the Wellcome Trust Centre for Human Genetics, University of Oxford. After a post-doctoral position at the CIMR, University of Cambridge, he joined the ICR in 2000.

  • Tak Mak
  • Tak W. Mak

    Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network

    E-mail: tmak@uhnres.utoronto.ca

Tak Mak is the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, Senior Scientist at the Ontario Cancer Institute, University Health Network, University Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.

Tak Mak is internationally known for his work in the molecular biology of cancer and the immune system, a world leader in the genetics of immunology and cancer. In 1984, he led the group that discovered the T cell receptor, and his published work on the cloning of T cell antigen receptor genes has been cited over 1,200 times. Since this landmark discovery, Tak Mak has focused on elucidating the mechanisms underlying immune responses and tumorigenesis. He pioneered the use of genetically engineered mouse strains to identify genetic susceptibility factors associated with various immune disorders or different types of cancer. In particular, his team discovered that CTLA4 is a negative regulator of T cell activation (cited 2000 times), paving the way for the development of anti-CTLA4 agents now in clinical use for autoimmune diseases. The Mak lab also made major contributions to defining the functions of PTEN (cited >2000 times) as well as the relationship between the breast cancer susceptibility genes BRCA1 and BRCA2 and defects in DNA repair. Most recently, Tak Mak’s studies of the functions of various gene products in normal and cancerous cells are yielding important information on their biology that is crucial for the identification of new drug targets and the development of more effective cancer therapies.

  • Richard Marais
  • Richard Marais

    Team Leader, Signal Transduction Team, Institute of Cancer Research, London, UK

    E-mail: Richard.marais@icr.ac.uk

Professor Marais is team leader of the Signal Transduction Team at the Institute of Cancer Research in London. He obtained a BSc (1985) in Genetics and Microbiology with 1st class honours from University College London and a Ph.D. (1989) in Comparative Studies on Protein Kinase C Isotypes from Ludwig Institute for Cancer Research, London. During his postdoctoral period (1989-1992) Professor Marais worked with Dr Richard Treisman at the Imperial Cancer Research Fund, London and (1992-1998) as Independent Postdoctoral Research Fellow at the Institute of Cancer Research, London. He is a Founder Scientist with Proacta Therapeutics Ltd., a small biotechnology company that focuses on cancer therapies and founded by the Institute of Cancer Research, Auckland University and the Cancer Research Campaign (Cancer Research Ventures) in October 2001 (now incorporated in the USA). Since 1999 he has received many grants to help finance his research, which has resulted in 10 patent applications.

His current research focuses mainly on signal transduction in the area of RAF protein. The BRAF gene is mutated in approximately 70% of melanomas and also at lower frequencies in many other cancers. Professor Marais and his team use molecular, cell and structural biology to examine the biological consequences of BRAF activation in melanoma and other cancers. They are also developing novel signal transduction inhibitors that can be used to treat human cancer and trying to understand how these drugs can be used to provide effective therapeutic approaches for melanoma. His other research interest is in gene therapy approaches to treat cancer, in collaboration with Professor Caroline Springer (Institute of Cancer Research).

Professor Marais is Secretary General of the European Association for Cancer Research (EACR) and member of several professional societies including the American Association for Cancer Research (since 2005), British Association for Cancer Research (since 1991), European Association for Cancer Research (since 2004). He is also a member of the steering committees for many national and international meetings.

He has authored over 90 original papers and reviews and has won several personal prizes: The British Association for Cancer Research/Zeneca Young Scientist of the Year (2001), Anniversary Prize of the Gesellschaft für Biochemie und Molekularbiologie (Society for Biochemistry Molecular Biology) (2003), EACR Young Cancer Researcher "Certificate of Merit"(2003).

Dr. Elaine Mardis graduated Phi Beta Kappa from the University of Oklahoma with a B.S. degree in zoology. She then completed her Ph.D. in Chemistry and Biochemistry in 1989, also at Oklahoma. Following graduation, Dr. Mardis was a senior research scientist for four years at BioRad Laboratories in Hercules, CA.

In 1993, Dr. Mardis joined The Genome Center at Washington University School of Medicine. As Director of Technology Development, she helped create methods and automation pipelines for sequencing the Human Genome. She currently orchestrates the Center's efforts to explore next generation and third generation sequencing technologies and to transition them into production sequencing capabilities.

Dr. Mardis has research interests in the application of DNA sequencing to characterize cancer genomes. She also is interested in facilitating the translation of basic science discoveries about human disease into the clinical setting.

Dr. Mardis serves on several NIH study sections, is an editorial board member of Genome Research, and acts as a reviewer for Nature and Genome Research. She serves as chair of the Basic and Translational Sciences Committee for the American College of Surgeons Oncology Group, a NCI funded cooperative group. She serves on the scientific advisory boards of Pacific Biosciences, Inc. and Edge Biosciences, Inc. Dr. Mardis received the Scripps Translational Research award for her work on cancer genomics in 2010, and has been named a Distinguished Alumni of the University of Oklahoma College of Arts and Sciences for 2011.

Dr Joan Massagué is Chairman of the Cancer Biology and Genetics Program at the Memorial Sloan-Kettering Cancer Center, New York City, and Investigator of the Howard Hughes Medical Institute. He is also a Professor at the Weill Graduate School of Medical Sciences and the Gerstner Sloan-Kettering Graduate School of Medical Sciences. He is Adjunct Director of the Barcelona Institute for Research in Biomedicine. He received his Ph.D. degree in biochemistry from the University of Barcelona in 1978, and was a postdoctoral fellow at Brown University. In 1982 he became Professor of Biochemistry at the University of Massachusetts Medical School until he assumed his current position in 1989.

Joan Massagué is interested in how growth factors, signaling pathways, and gene expression programs control normal cell behavior and cancer cell metastasis. He elucidated fundamental machinery that conveys growth inhibitory signals from the cell membrane to the nucleus. Combining cell biology, biochemistry and genetics, he identified the TGF-?? receptors and their mechanism of activation. Building on this, he discovered that the Smad proteins are TGF-? receptor substrates and transcriptional activators, thereby establishing the central concept of how this pathway operates. An end result of this process, Massagué found, is the inhibition of cell division through novel CDK inhibitors that he co-discovered. His work provided a direct explanation for how external signals block mammalian cell division. These mechanisms are now known to be crucial in embryonic development, and their disruption causes tumor formation and metastasis. Building on these advances, Dr. Massagué has recently identified genes and mechanisms that mediate the ability of breast tumors to form metastasis in vital organs, answering long-standing questions and opening new avenues of investigation into this devastating aspect of cancer. Dr. Massagué has published over 250 papers on these topics and is ranked among the 50 most highly cited scientists of the past 20 years.

Dr. Massagué has served as an advisor to the National Institutes of Health, the National Cancer Institute, the MD Anderson Cancer Center, the Fox Chase Cancer Center, the Searle Foundation, and the General Motors Foundation, and in the editorial boards of The Journal of Biological Chemistry, The Journal of Cell Biology, The Journal of Clinical Investigation, EMBO Journal, and the Proceedings of the National Academy of Sciences.

Dr. Massagué is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Academy of Microbiology, the Spanish Royal Academies of Medicine and Pharmacy, and the European Molecular Biology Organization. He is the recipient of the King Juan Carlos Prize, the Prince of Asturias Prize, the Vilcek Prize, and the Passano Prize, among other honors.

Gerry Melino

Professor Gerry Melino, MD (Rome), PhD (London), Dr Sci hc (St Petersburg), working at the MRC Toxicology Unit (Leicester UK) and at the University Tor Vergata of Rome (Italy), has created the major forum for discussion and innovation in the field of cell death in the last twenty years. In fact, his editorial contribution to the scientific community has been pivotal, being the Founder & Editor-in-Chief of the journals “Cell Death Differentiation” (www.nature.com/cdd), “Cell Death Disease” (www.nature.com/cddis) and “Cell Death Discovery” (www.nature.com/cddiscov), of impact factor 8.5, 6.0 and 2.5 respectively. His scientific interest focuses upon programmed cell death in epidermal and cancer models, and in particular on the p53 family - p63 and p73, where his contribution has been fundamental.

            Awards: (2009) Feltrinelli Prize by Academia Lincei (founded 1602) presented by President of Italy.  (2010) Antonini Prize, Italian Society Biochemistry. (2011) Morgagni Medal. Morgagnane Lectures 250th Anniversary. University Padua. (2012) Doctor Science Honorary Degree, Saint Petersburg Institute Technology. (2013) Chancellor’s Award on Neuroscience. Louisiana State University, USA. (2014) Honorary Professor & Advisory at Shanghai Jiao Tong University, School of Medicine, China. (2015) Senate Medal. Cancer Centre. Hawaii State, USA. (2016) Distinguished Career Award, European University of Cyprus.

His Training originated in Italy and in particular Rome, where he obtained his MD (1978, University of Rome) followed by clinical specialisations in Paediatrics (1981, University of Rome) and Clinical Oncology (1985, University of Rome).  Following his PhD in 1979-1984 at the University of London in the Chemical Pathology Department, Charing Cross & Westminster Medical School, he worked as Research Fellow, then Lecturer and later Senior Lecturer (Honorary Consultant) until 1987. Professor Melino returned to Italy in 1988 to the University of Rome as a Lecturer before becoming a full Professor in 1994. Professor Melino has acted as Consultant and Scientific Advisor for several companies and government institutions.

The Scientific Interests of Professor Melino are focused on Programmed Cell Death or apoptosis, in neural and epidermal models.  Originally, he worked on the  Molecular mechanisms of cell death in the skin, a process known as cornification or formation of the cornified envelope.  The molecular events were investigated in vitro and in animal models as well as in human genetic pathologies.  The role of transglutaminases (type 1, 2, 3, and 5) and their substrates (SPRs, loricrin, keratins) were investigated at biochemical and genetic levels.  While still keeping an interest on these aspects, his current work is focused on The p53/p63/p73 family. DNA damage elicit repair mechanisms involving the tumour suppressor gene p53 and the two newer members of the same family: p63 and p73. The molecular events driven by DNA damage to elicit the function of p63/p73 and their transcriptional regulation, is investigated in vitro. The molecular mechanisms of apoptosis and their protein stability and degradation is also under investigation. Transgenic mice and knock-outs for p63/p73 is in progress.

Cites, ISI: 26185 cites, H-index 75 (Scopus: 27207 cites, 80 H-index) (GS: 39745 cites, H-index 92).

Clinical Discoveries: 1. Mutations K13 cause Cannon’s White Spongious Nevous (OMIM #193900).
2. Mutations FADH long chain fatty acid acidi cause Sjogren-Larsson Syndrome (OMIM #270200).
3. Mutations TG1 cause Lamellar Icthyosis (OMIM #242300). 4. Mutations TG2 cause MODY type 7 (OMIM #606391). 5. Mutations TG5 cause Acral Esfoliatative Syndrome (OMIM #606391). 6. Mutations U2HR cause Marie Unna’s hypo thrycosis (alopecia) (OMIM #146550). 7. Identified New Disease: Unilateral Palmoplantar Verrucaeus Nevous (OMIM #144200).

Dr. John Mendelsohn was born in Cincinnati and earned his bachelor's degree in biochemical sciences magna cum laude from Harvard College in 1958. While there, he was the first undergraduate student of Dr. James D. Watson, who later won the Nobel Prize in Medicine for identifying the structure of DNA. Dr. Mendelsohn received his medical degree cum laude from Harvard Medical School in 1963. He was founding director of the Cancer Center at the University of California, San Diego, and served as chairman of the department of medicine at Memorial Sloan-Kettering Cancer Center for eleven years.

Dr. Mendelsohn combines experience in clinical and laboratory research with administrative expertise for guiding The University of Texas M. D. Anderson Cancer Center in the new century. Since becoming president in July 1996, he has recruited a visionary management team and implemented new priorities for integrated programs in patient care, research, education and cancer prevention.

For almost three decades, Dr. Mendelsohn has been at the forefront in understanding how growth factors regulate the proliferation of cancer cells by activating receptors on the surface of the cells. These receptors, when activated, control key cell signaling pathways. He and his colleagues developed a specific monoclonal antibody called Cetuximab (Erbitux TM), which blocks the activity of the receptor for epidermal growth factor. Their publication in 1983 was the first demonstration of an anticancer therapy which targets a growth factor receptor and a tyrosine kinase, and their publication in 1991 was the first clinical trial testing this approach in cancer patients. Subsequent clinical studies have demonstrated that therapy combining this antireceptor antibody with chemotherapy or radiation is effective treatment for patients with several forms of cancer. On February 12, 2004, the FDA approved Erbitux TM for treatment of advanced colorectal cancer, and on March 1, 2006 for treatment of head and neck cancer.

Dr. Mendelsohn served as the founding editor of Clinical Cancer Research, a bimonthly clinical research journal published by the American Association for Cancer Research. He has authored more than 250 scientific papers and articles for journals and a textbook on the Molecular Basis of Cancer. Dr. Mendelsohn's past honors include the Gold Medal of Paris, the Joseph H. Burchenal Clinical Research Award from the American Association for Cancer Research, and The Breast Cancer Research Foundation's Jill Rose Award. He was elected to membership in the Institute of Medicine of the National Academy of Sciences. In May 2002, he received the Simon Shubitz Prize from the University of Chicago. He was honored with the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology in 2002, and received the Bristol-Myers Squibb Freedom to Discover Award for Distinguished Achievement in Cancer Research in October 2004. In April 2005 he and his wife were jointly honored for public service by the Woodrow Wilson International Center for Scholars. In May 2005 he received the Fullbright Lifetime Achievement Medal which was created to honor Fullbright alumni whose distinguished careers and civic and cultural contributions have sought to expand the boundaries of human wisdom, empathy, and perception. In May 2006, he received the Dan David Prize in the Future Time Dimension at Tel Aviv University for pioneering the rapidly developing modality of antibody-mediated cancer therapy in general and that of antibodies to growth factor receptors in particular.

Dr. Mendelsohn and his wife, Anne, jointly participate in multiple civic activities. Dr. Mendelsohn is an active member of the Greater Houston Partnership (Board), the Houston Technology Center (Board), BioHouston (Vice-Chairman), the Center for Houston's Future (Board) and the Houston Forum. The Mendelsohns have three sons.

In 1994, Dr. Gordon B. Mills was recruited to The University of Texas M. D. Anderson Cancer Center, where he holds the rank of professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology; serves as chairman of the Department of Systems Biology; head of the section of Molecular Therapeutics and holds the Ann Rife Cox Chair in Gynecology. Dr. Mills is co-Director of the newly formed Kleberg Center for Molecular Markers and director for the new SCRBII Molecular Markers building to be opened this fall.

With more than 300 publications either published or in press, Dr. Mills has authored papers in such prestigious journals as Nature, Cell, Oncogene, Nature Genetics, Nature Medicine, Cancer Research, Proceedings of the National Academy of Sciences and Clinical Cancer Research. A testament to the quality of his research, Dr. Mills' work in ovarian cancer, breast cancer and tumor immunology has been continuously funded by major peer-reviewed grants for 20 years. He serves as principal investigator on five NIH/NCI grants and three Department of Defense grants, co-principal investigator on two NIH/NCI grants and one Department of Defense grant, and collaborator on multiple other national peer-reviewed grants.

Dr. Mills has made significant contributions to the understanding of ovarian tumorigenesis, including the identification and development of lysophosphatidic acid (LPA) as a possible marker for early-stage ovarian cancer and as a potential target for therapy. He also has played a major role in increasing our understanding of the genetic aberrations in the phosphatidylinositol 3 kinase/PTEN/AKT pathway, forwarding this cascade as a major target for the therapy of multiple types of cancer.

Dr. Mills is the holder of more than 20 patents related to novel technologies and molecular markers. He was a co founder of an early diagnostics company. He currently sits on the scientific advisory boards of multiple different companies and venture capital groups. Based on his expertise in technology development, he is the head of the MD Anderson Cancer Center Technology Review Committee.

Dr. Mills now heads the Kleberg Center for Molecular Markers. This Center holds the responsibility for developing personalized molecular medicine at the MD Anderson Cancer Center. Specifically, this center will implement a series of novel technologies to for the first time explore the genetic changes and their consequences at the DNA, RNA and protein levels in human tumors. This information will be used to identify patients at high risk for tumor development so they can be triaged to early screening and chemoprevention, identify markers to use in early screening, and to determine approaches to ensure that patients receive the most effective and least toxic therapies targeting the underlying genetic aberrations in tumors.

Dr. Mills earned his M.D. and his Ph.D. in biochemistry from the University of Alberta. From 1985 to 1994, Dr. Mills was a member of the faculty of the University of Toronto, rising to the rank of Associate Professor in the departments of Obstetrics and Gynecology, Immunology, and Clinical Biochemistry. Also during this time, he was an active staff member and director of Oncology Research at the Toronto Hospital.

Moshe Oren is professor at the Department of Molecular Cell Biology, Weizmann Institute of Science, Israel. In 1982, together with Dr. Arnold Levine, he cloned the p53 gene. In 1989, the Oren group demonstrated that wild type (wt) p53, but not cancer-associated mutants thereof, can suppress oncogenic transformation, thereby providing experimental evidence for p53 being a tumor suppressor. In 1991, the Oren group reported that p53 can induce apoptosis in cancer cells. More recently, along with Dr. A. Levine, the Oren group first reported that p53 regulates the transcription of the Mdm2 gene and, along with Dr. K. Vousden, that the Mdm2 protein promotes the ubiquitination and degradation of p53, defining an autoregulatory loop that is of great importance in human cancer.

  • Pier Paolo Pandolfi, MD, PhD

    George C. Reisman Professor of Medicine
    Professor of Pathology, Harvard Medical School
    Director, Cancer Center and Cancer Research Institute
    at Beth Israel Deaconess Medical Center
    Boston, MA, USA

Pier Paolo Pandolfi, MD, PhD, received his MD in 1989 and his PhD in 1995 from the University of Perugia, Italy after having studied Philosophy at the University of Rome, Italy. He received his post-graduate training at the National Institute for Medical Research and the University of London in the UK. 

Following his tenure as a faculty member at Memorial Sloan-Kettering Cancer Center in New York starting in 1995, he joined the Harvard Medical School (HMS) faculty at Beth Israel Deaconess Medical Center (BIDMC) in 2007 to serve as Scientific Director of the Cancer Center and Chief of the Division of Genetics in the Department of Medicine. Dr. Pandolfi currently holds the Reisman Endowed Chair of Medicine and is Professor of Medicine and Pathology at HMS. He was then appointed in 2013 to serve as the Cancer Center Director and the Director of the Cancer Research Institute at BIDMC and HMS.

Dr. Pandolfi has been the recipient of numerous awards for his research, including, in 2011, the Pezcoller Foundation–AACR International Award for Cancer Research. He is a member of the American Society for Clinical Investigation, American Association of Physicians, and European Molecular Biology Organization among others. On June 2, 2015, Dr. Pandolfi was Knighted by the president of the Italian Republic and received the Medal of Honor as “Officer of the Order of the Star of Italy”. In 2015 he was also awarded the prestigious Outstanding Investigator Award from the NIH/NCI and very recently he has been named Fellow of the American Association for the Advancement of Science (AAAS).

The research carried out in Dr. Pandolfi’s laboratory has been seminal to elucidating the molecular mechanisms and the genetics underlying the pathogenesis of leukemias and solid tumors. Dr. Pandolfi and colleagues have characterized the function of the fusion oncoproteins and the genes involved in the chromosomal translocations of acute promyelocytic leukemia (APL), as well as of major tumor suppressors such as PTEN and p53, and novel proto-oncogenes such as POKEMON.  The elucidation of the molecular basis underlying APL pathogenesis has led to the development of novel and effective therapeutic strategies. As a result of these efforts, APL is now considered a curable disease. More recently, Dr. Pandolfi and colleagues have presented a new theory describing how mRNA, both coding and non-coding, exerts their biological functions with profound implications for human genetics, cell biology and cancer biology. 

  • Klaus Pantel
  • Klaus Pantel

    Chairman of the Institute of Tumour Biology, University Medical Center Hamburg-Eppendorf, Germany

    E-mail: pantel@uke.de

Prof Klaus Pantel graduated in 1986 from Cologne University in Germany and completed his thesis on mathematical modelling of hematopoiesis in 1987. After his postdoctoral period in the USA on hematopoietic stem cell regulation (Wayne State University, Detroit), he performed research on cancer micrometastasis at the Institute of Immunology, University of Munich for 10 years. Currently, Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 300 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, PNAS, JCO, JNCI, Cancer Res.) and has been awarded recently (AACR Outstanding Investigator Award 2010, German Cancer Award 2010, ERC Advanced Investigator Grant 2011). Moreover, Prof Pantel was co-ordinator of the FP6 EU STREP “DISMAL” (Disseminated Malignancies, www.dismal-project.eu), coordinates now the European TRANSCAN group “CTC-SCAN” and serves on the Editorial Boards of international cancer journals (e.g., Clin. Cancer Res., Breast Cancer Res., Cancer Res.).

  • Daniel Peeper
  • Daniel S. Peeper

    Professor in Functional Oncogenomics, heading the Department of Molecular Oncology and chair of both the Scientific Faculty Council and the Translational Research Board at the Netherlands Cancer Institute (NKI).

    Website: https://www.nki.nl/
    E-mail: d.peeper@nki.nl

Daniel Peeper is a professor in Functional Oncogenomics heading the Department of Molecular Oncology and chairing both the Scientific Faculty Council and the Translational Research Board at the Netherlands Cancer Institute (NKI). He has received several awards, including a Queen Wilhelmina Award and and a Society for Melanoma Research (SMR) Outstanding Researcher Award. He is an EMBO member and serves on several Boards, including that of the European Association for CancerResearch. His laboratory discovered the physiologic relevance of Oncogene-­Induced cellular Senescence (OIS) and deciphered several of its key mechanisms. Most recently, his lab has been focusing on translational aspects of melanoma development, designing in vivo genetic screens for drug target identification and unraveling mechanism mediating resistance to targeted and immunotherapy. Several potential new drug targets and combinations have been patented and are currently being studied for clinical follow-­‐up.

  • Martine J. Piccart

    Professor of Oncology at the Université Libre de Bruxelles (ULB) and Director of the Medicine Department at the Institut Jules Bordet, in Brussels, Belgium.

    Website: http://www.bordet.be
    E-mail: martine.piccart@bordet.be

Dr. Piccart earned her M.D. and Ph.D. at the Université Libre de Bruxelles, Belgium, and received her oncology qualifications in New York and London. She is a member of the "Acadé mie Royale de Mé decine de Belgique".

With a primary interest in breast cancer and drug development, Dr. Piccart has a strong interest in international research collaboration, and is the principal or co-principal investigator of many clinical trials, including HERA, MINDACT, and ALTTO. She is co-founder and chair of the Brussels-based Breast International Group (BIG), created in 1996 to facilitate international breast cancer clinical trials, and TRANSBIG, a European Commission supported translational research consortium to complement BIG's clinical research network. BIG brings together 44 collaborative groups from around the world and has over 30 trials under its umbrella; TRANSBIG represents 39 institutions in 21 countries; and BIG has recently launched an innovative biomarker and drug development program focused on neo-adjuvant trials, called NeoBIG.

Dr. Piccart is an active member of many professional organizations, currently serving as president-elect of the European Society for Medical Oncology (ESMO). She is immediate past-president of the European Organization for the Research and Treatment of Cancer (EORTC) and recently served on the American Society of Clinical Oncology (ASCO) Board.

She is author or co-author of more than 300 scientific publications in peer-reviewed journals and has received numerous prestigious awards for her contribution to research in oncology, including the ESMO Award for Exceptional Contribution to the Advancement of Medical Oncology in Europe (1997), a "Jacqueline Seroussi Memorial Foundation for Cancer Research Award" for "International leadership in translational and clinical research that has improved treatment outcomes for women with early stage and advanced breast cancer" (2005), the 14th Claude Jacquillat Award for achievements in clinical oncology (2006) and the ESMO-GSK Lifetime Achievement Award in Breast Cancer Research (to the Breast International Group in 2006). She was awarded the "Miami Breast Cancer Conference Award of Excellence for 2007" and the Jill Rose Award for distinguished biomedical research in October 2009 in New-York. More recently, Dr Piccart received the William L. McGuire Award in recognition of her contribution in breast cancer research in December 2009 in San Antonio.

Dr. Piccolo received his PhD from the University of Padua, Italy. He trained as post-doctoral fellow with Eddy De Robertis in HHMI-UCLA, to then return to Padua where he is currently Professor of Molecular Biology at the School of Medicine. Dr. Piccolo unveiled new mechanisms by which cells sense their environment and use this information to build and maintain tissues with specific form, size and function. Dr. Piccolo also showed how disruption of these homeostatic mechanisms leads to tumor formation, progression and metastasis. Current main research topics are on Mechanotransduction, Wnt and Hippo pathways and how these signals regulate adult stem cells and cancer stem cells.

  • Jeffrey W. Pollard

    Deputy Director, Cancer Center, Albert Einstein College of Medicine and Director, Center for the Study of Reproductive Biology and Women's Health, Albert Einstein College of Medicine, New York, NY, USA

    Website: http://www.aecom.yu.edu/home
    E-mail: pollard@aecom.yu.edu

Since 2003, Dr Pollard is Deputy Director of the Cancer Center, Albert Einstein College of Medicine and also Director of the Center for the Study of Reproductive Biology and Women's Health of the same institute. He received his Ph.D. in 1975 while with the Imperial Cancer Research Fund, UK, and was a postdoctoral fellow at the Ontario Cancer Institute, Canada (1975-1979). He returned to the UK to take up an appointment as lecturer at Kings's College, University of London (1980-1988). In 1988 he was appointed Associate Professor of the Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, and became Professor of the department in 1993. In the same year also became Professor of Obstetrics and Gynecology and Women's Health.

Dr Pollard's research interests focus on the role of the tumor micro-environment in modulating tumor progression and metastatic potential; tumor educated macrophages and cancer; mechanism of action of female sex steroid hormones in regulating cell proliferation in vitro; placental immunity.

David Ransohoff is a physician trained in clinical epidemiology (clinical epidemiology is the field of research methodology for questions about diagnosis, prognosis, and response to therapy). While training at Yale with one of the founders of the field of clinical epidemiology, he and his mentor Alvan Feinstein wrote a seminal paper about ''rules of evidence' to evaluate studies of diagnostic tests' (Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299(17):926-930). Building on a research career about non-molecular diagnostic tests, he extended his work, beginning about 10 years ago, to include 'molecular markers for cancer.' He has worked in genomics (N Engl J Med 2004;351(26):2704-2714) and in proteomics (with NCI's Early Detection Research Network (EDRN) and Clinical Proteomic Technology Assessment for Cancer (CPTAC); work in publication and in preparation). His major interest is research methodology -- in translating or applying 'rules of evidence' that may improve methods to design, conduct, and interpret research about molecular markers for cancer. (Nat Rev Cancer 2004;4(4):309-314; Nat Rev Cancer 2005;5(2):142-149; J Clin Epidemiol 2007;60(12):1205-1219).

  • Jorge Reis-Filho

    Professor of Molecular Pathology
    The Breakthrough Breast Cancer Research Centre, London, UK

    E-mail: reisfilj@mskcc.org

Professor Reis-Filho holds a joint medical degree from University of Porto, Portugal and Universidade Federal do Parana, Brazil. After finishing his histopathology training at the Institute of Molecular Pathology and Immunology, University of Porto, Portugal, he did his PhD on breast cancer molecular pathology at the Breakthrough Research Centre where he was appointed Team Leader of the Molecular Pathology Laboratory in 2006. In 2007, Prof. Reis-Filho was awarded the CL Oakley Lectureship by the Pathological Society of Great Britain and Ireland and the BACR Translational Research Award. In 2010, Prof. Reis-Filho was awarded the 2010 Ramzi Cotran Young Investigator Award by the United States and Canadian Academy of Pathology and the Future Leaders Prize by Cancer Research UK. Prof. Reis-Filho is the youngest ever Fellow of The Royal College of Pathologists to have become a member by published works. Professor Reis-Filho is an elected member of the Council of the Pathological Society of Great Britain and Ireland, and a member of the Cancer Research UK Biomarkers & Imaging Discovery & Development Committee. He is the International Editor of Advances in Anatomic Pathology, associate editor for molecular pathology of The Journal of Clinical Pathology and BMC Cancer, and a member of the editorial boards of Science Translational Medicine, The Journal of Pathology, Modern Pathology, Laboratory Investigation, and of the international advisory board of the Archives of Pathology and Laboratory Medicine.

Prof. Reis-Filho's research programme focuses on i) the development of an integrated morphological and molecular classification for breast cancer and melanomas and ii) the identification of novel therapeutic targets for specific subgroups of breast cancer and melanoma patients, through an integrative analysis of data derived from histopathology, high throughput transcriptomic and genomic profiling methods, massively parallel sequencing and functional genomics.

Education and Professional History
1982: graduated from Tohoku University School of Medicine, Sendai, Japan and obtained M.D.
1982: entered Tohoku University Graduate School of Medicine, Sendai, Japan.
1983 - 1985: trained as a Fulbright exchange research and clinical fellow at Division of Pediatric Endocrinology, Department of Pediatrics, The New York Hospital, Cornell Medical Center, NY, USA.
1986: graduated from Tohoku University Graduate School of Medicine and obtained Igaku-Hakushi, or Ph.D.
1986 - 1989: resident of anatomic pathology at The George Washington University Hospital, and assistant at Department of Pathology, The George Washington University Medical Center, Washington D.C., USA.
1989 - 1998: Assistant Professor, Department of Pathology, Tohoku University School of Medicine and attending pathologist, Tohoku University Hospital, Sendai, Japan.
1998 - present: Professor, Department of Pathology, Tohoku University School of Medicine, Sendai, Japan and Director, Department of Pathology, Tohoku University Hospital, Sendai, Japan

Research Interest: steroid biosynthesis, metabolism and actions, steroid dependent cancer.

Academic Societies:
U.S. Canadian Academy of Pathology
U.S. Canadian Academy of Pathology (regular member)
The Endocrine Society (regular member, Committee members)
International Society of Gynecological Pathology (regular member)
Japan Endocrine Pathology Society (Council, Executive Committee)
The Japan Endocrine Society (Council, Executive Committee)
Japanese Society of Gynecologic Oncology (Council, Executive Committee)
The Japanese Steroid Hormone Society (Council, Executive Committee)
The Japanese Pathology Society (Council, Executive Committee)
The Japanese Reproductive Endocrinology Society (Council, Executive Committee)
The Society of Cardiovascular Endocrinology and Metabolism (executive member)
The Japanese Cancer Association (exexutive member)
The International Society of Breast Pathology (regular member)

In 1998, Joan Seoane obtained his PhD in Biochemistry and Molecular Biology from the University of Barcelona. Previously, in 1993, he had obtained his BSc degree in Chemistry, branch of Biochemistry and Molecular Biology. Joan joined the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York as a post-doctoral fellow in 1998. From 1998 to 2001, he worked as a Research Fellow at this institution and subsequently, from 2001 to 2003, as a Research Associate. He was appointed ICREA Research Professor in 2004 and established his own Group back in Barcelona at the Vall d'Hebron Institute of Oncology (VHIO). In 2007, he became a member of the EMBO Young Investigator program. In 2008, he was the recipient of a European Research Council grant, became Board member of the European Association of Cancer Research (EACR) and Associate Professor at the Universitat Autònoma Barcelona (UAB). Since 2011, Joan is the Director of the Translational Research program at VHIO within the Vall d'Hebron University Hospital. He is also the recipient of several awards such as the MSKCC Research Fellow Award, the Banco Sabadell Award for Biomedical Research, and the Dr. Josef Steiner Award.

Dr. Seoane's main objective is to understand the molecular mechanisms involved in the initiation and progression of cancer. Specifically, his research is focused on the study of brain tumors. The understanding of the molecular mechanisms that govern brain tumors is required in order to design rational, specific and successful therapeutic approaches.

  • Alan Spatz

    Head, Immunophenotype and Biopsies Unit, Institut Gustave-Roussy (IGR), Montreal, Canada

    E-mail: alan.spatz@mcgill.ca

Alan Spatz is a pathologist and Head of the Immunophenotype and biopsies Unit at the Institut Gustave-Roussy (IGR), France. He received his medical degree (1992) and his pathology certification (1992) at the Paris University (PARIS XI). Dr Spatz is a member of numerous professional organizations including the European Organization for Research and Treatment of Cancer (EORTC), the American Association for Cancer Research (AACR), the International Academy of Pathology (IAP), and the European Society of Medical Oncology (ESMO). He has served EORTC in various capacities, such as Chairman of the EORTC Melanoma group, Chairman of the EORTC Pathology group, member of the Translational Research Advisory Committee, and co-Chairman of the US NIC-EORTC working group on tissue repositories. He has recently been elected member of the EORTC board.

Dr Spatz has participated in numerous international meetings, serving as faculty, discussant, and Session Chair. He is also the President of the French division of the IAP. He plays an active role in translational research, and has been particularly involved in the characterization of key molecular defects associated with melanoma progression ad pre-neoplasic changes associated with BRCA-1 related ovarian cancers. He ahs also directly contributed to the European standards for melanoma pathology report and the establishment of a clinical trials-related tissue bank within the EORTC.

In 2006 Dr Spatz was elected Chairman of the EORTC Melanoma group. The EORTC Melanoma group is the main melanoma clinical trial network in Europe and has a tracking record of fast accrual in stage III and stage IV melanomas.

Dr Spatz has served as author or co-author of 95 scientific publications in peer-reviewed journals and textbooks.

  • Paul Spellman
  • Paul Spellman

    Professor, Department of Molecular and Medical Genetics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

    E-mail: spellmap@ohsu.edu

Dr. Paul Spellman is a Professor of Molecular and Medical Genetics at Oregon Health & Science University in Portland, Oregon and is the Program Lead in Quantitative Oncology within the Knight Cancer Institute working to integrate data intensive sciences into cancer research. Dr. Spellman received his Ph.D. in Genetics from the Stanford University School of Medicine in 2000 and was a postdoctoral fellow at UC Berkeley. Dr. Spellman was a Scientist and later Staff Scientist at Lawrence Berkeley National Laboratory from 2003 until 2011. In 2011 he was Special Assistant to the Deputy Director of the NCI before joining Oregon Health & Science University that same year as an Associate Professor. In 2013 Dr. Spellman was promoted to Professor.

Dr. Spellman interests are in using genetic, genomic, and proteomic data to understand and model the biology of cancer with the goal of effectively deploying therapeutic agents in the age of molecularly guided medicine. Members of his lab use a combination of conventional molecular biology, high throughput genomic and proteomic assays, and bioinformatic analyses in their work. Dr. Spellman has been a leader in genomic technologies for nearly 20 years with a focus on application to driving scientific questions. Dr. Spellman is a member of both The Cancer Genome Atlas and the International Cancer Genomics Consortium. Other recent areas of research include predictors of therapeutic response in breast cancer; the systematic reconstruction of aberrant signaling networks in cancer; and the development of methods to infer early events in tumors. In total Dr. Spellman has authored 86 papers and reviews and is the PI of three NIH grants.

Dr. Spellman serves as an advisor to NIH in various capacities. Currently, Dr. Spellman is a permanent member of the Cancer Genetics study section and serves on the National Cancer Advisory Board, ad hoc Information Technology Working Group. In addition, Dr. Spellman is an internal member of the advisory board for the Pacific Northwest Prostate Cancer SPORE and as an external advisor to the Canadian Prostate Cancer Genome Network.

  • Josep Tabernero
  • Josep Tabernero

    MD Head, Medical Oncology Department, Vall d’Hebron University Hospital Barcelona, Spain

    E-mail: jtabernero@vhio.net

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology. He is very actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies. He is especially devoted to phase I and II studies with pharmacodynamic endpoints with novel agents directed to the membrane receptors, like the EGFR-family and IGF-1R, the PI3K and ERK signalling pathways, as well as downstream cytoplasmatic and intranucleous effectors like Mdm2/p53 and aurora kinase. Based in the idea that each tumor has an independent genetic identity, the group he is leading very actively participates in the development of molecular therapies targeting specific oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR or IGF1-R among others) for those patients displaying genetic lesions or pathway disregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments and to identify markers of primary resistance (de novo) and secondary treatment. At a preclinical level, the group he is leading is developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study the tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).

In addition, Dr. Tabernero is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), and different Editorial Boards including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer, The Oncologist and Annals of Oncology. He has (co)authored approximately 250 peer-reviewed papers; 100 as first, second or senior author. He has also been member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC (ESMO GI) meetings.

David Tarin began his research career in 1960 using one of the first electron microscopes installed in Britain to study collagen formation in the skin of Amphioxus, a marine protochordate. Having graduated with a Science degree from the University of Leeds, he went on to study Medicine at the University of Oxford graduating in 1963. He then held Faculty appointments as a surgical pathologist at teaching hospitals in the Universities of Birmingham and Leeds and at the Royal Postgraduate Medical School, Hammersmith Hospital, University of London from 1965 to 1979. During this period he focused and on basic science research on cancer, developmental biology and wound healing and demonstrated interactions between tumor cells and neighboring host tissues, leading to the development of the concept of the tumor micro-environment (summarized in Tarin, D. Tissue interactions in Carcinogenesis Academic Press, London 1972).

In 1979 he moved to Oxford University where he became Nuffield Professor of Pathology, Director of the Cancer Diagnosis and Metastasis Research Laboratory and Attending Surgical Pathologist to the United Oxford Hospitals. There he founded and served as chairman and coordinator of the Oxford Breast Diseases Group for 18 years. This consortium of surgeons, medical oncologists, radiotherapists, radiologists and pathologists met weekly to decide the management and care for each breast cancer patient referred to the John Radcliffe Hospital, Oxford. The aim was to bring patients the benefits of a caring, coordinated and multidisciplinary team approach to cancer care. Concurrently he conducted research on mechanisms of cancer metastasis (see Tarin et al. 1984, Cancer Res 44:3584 3592) and early cancer detection using molecular markers such as CD44 (Matsumura et al,1992, Lancet 340:1053 1058).

In 1997 he moved to the University of California, San Diego where he became Director of the UCSD Cancer Center and Associate Dean for Cancer Affairs at UCSD School of Medicine. Here he oversaw the creation of the John and Rebecca Moores, UCSD Cancer Center in a dedicated new building and secured designation of this institute as one of 37 elite Comprehensive Cancer Centers recognized by the National Cancer Institute of the United States. After this he relinquished the Directorship in 2003 to return to research, clinical interests and teaching as a Professor in the Department of Pathology at UCSD.

Tarin's laboratory research has recently focused on the cellular and molecular mechanisms involved in the spread of cancer in the human body (metastasis), and genes that program tumor cells to thus colonize distant organ (see Montel et al. Am J Path. 2005, 166:1565-1579; Montel et al. 2006, Int J Cancer 119, 251-263 ;Suzuki et al 2006, Am J Path.169:673-81. His clinical research has concentrated on using the exceptionally sensitive, non-invasive methods now available in molecular genetics to facilitate early cancer diagnosis. Woodman et al. 2000, Clin Canc Res. 6:2381-2392

He is the former president of the International Society of Differentiation, and has served on the editorial boards of several journals, including Cancer Research, Journal of Clinical Pathology, Journal of Pathology, Differentiation, and Molecular Diagnosis. He has been a scientific referee for various peer-reviewed international journals including Nature, Science, Lancet and the British Journal of Cancer.

  • Thomas Tursz

    Professor Thomas Tursz Director, Institut Gustave-Roussy (IGR), Villejuif, France (since October 1994) Director of the Doctoral School of Oncology: "Biology-Medicine-Health" since 2000 President of the French Federation of Comprehensive Anticancer Centres (FNCLCC) since 2004 Chairman SAC of the EORTC (since 2003) and Vice-President of EORTC Board since 2006 President of the OECI (2002-2005) and Chairman

    Website: http://www.igr.fr
    Email: Thomas.tursz@gmail.com

Professor Thomas Tursz was born in Krakow, Poland in 1946. Thomas Tursz is both a medical oncologist and a researcher. He was the Director of the CNRS** Biology of Tumours Laboratory (URA CNRS 1156) at the IGR from 1984 to 1996 and Head of the Department of Medicine from 1992-1994. He was President of the International Association for Research on the Epstein-Barr Virus and Associated Diseases from 1994 to 1996. From the clinical point of view, his Department has conducted several important trials in breast, lung cancer and soft tissue sarcomas and was a pioneer in France of cytokines and gene therapy in human clinical trials. Former Secretary of the Soft Tissue and Bone Sarcoma Group of the EORTC, he was Chairman of this Group from 1993 to 1996. In 1994, the first trial on gene therapy in lung cancer using a recombinant adenovirus was initiated in his department at the Institut Gustave Roussy. His work has been awarded several prestigious scientific prizes such as the Oncology Award "Prix de Cancé rologie" from the French National League Against Cancer in 1979, the Bernard-Halpern Immunology Award in 1983, the Rosen Oncology Award from the Medical Research Foundation in 1989 and the Grand Prix in Oncology from the Academy of Medicine in 1992, the Hamilton Fairley Award for Clinical Research from the European Society of Medical Oncology (ESMO) in 1998 and the Prix de Rayonnement Français in 2001. He is the author of 350 international papers in peer-reviewed journals including Sciences, Nature, PNAS, JNCI, JCO, J. Biol. Chem., EMBO J., Lancet, Lancet Oncology, Brit Med J.

Dr. Mark L. Tykocinski serves as Dean of Jefferson Medical College and Senior Vice President of Thomas Jefferson University. He also is President of Jefferson University Physicians, the faculty practice plan. As Dean of Jefferson Medical College, Dr. Tykocinski has primary responsibility for the quality of the school's medical education. In addition, he guides the research mission of the college and its nearly 1,000 full-time faculty. Before his current appointment in 2008, Dr. Tykocinski was professor and Chair of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine for 10 years. Under his leadership, the department now ranks first in National Institutes of Health (NIH) funding among departments of pathology in the country. Dr. Tykocinski built a comprehensive clinical services infrastructure at Penn, encompassing clinical laboratory and tissue diagnostics and transfusion medicine. His department also featured leading residency and fellowship programs, considered by many to be among the top in the country. Dr. Tykocinski holds several research patents in the fields of molecular and cellular immunology. His work has focused on the design of novel fusion proteins with immunotherapeutic potential, as well as unique cellular engineering strategies that invoke these proteins. In his career, he also pioneered a novel class of eukaryotic expression vectors, which are now widely used by other laboratories around the world. He is the President of the Association of Pathology Chairs, and is past-president of the American Society for Investigative Pathology. In 1995, Dr. Tykocinski was honored with the Warner-Lambert/Parke-Davis Award for Outstanding Research from the American Society for Investigative Pathology. Dr. Tykocinski earned a bachelor of arts degree in biology magna cum laude from Yale University and was awarded his medical degree from New York University. He completed an internal medicine internship at Columbia-Presbyterian Medical Center in New York City and residency training in anatomic pathology in the Department of Pathology at New York University.

Professor Axel Ullrich was trained as a biochemist at the University of Tuebingen (Germany) and earned a Ph.D. in Heidelberg in Molecular Genetics in 1975. After a postdoctoral tenure at the University of California, San Francisco, he joined Genentech in 1978. His work in the field of signal transduction research has elucidated major fundamental molecular mechanisms that govern the physiology of normal cells and allow insights into patho-physiological mechanisms of major human diseases such as cancer.

For over 30 years Professor Ullrich has been a leader in gene-technology, translating basic science discoveries into medical applications. This led in the mid eighties to the development of Humulin (human insulin for the treatment of diabetes; Lilly), the first therapeutic agent to be developed through gene-based technology and the first biotechnology product ever. Another biotech product that is based on Professor Ullrich's work is Herceptin, the first target-directed, gene discovery-based cancer therapy for the treatment of metastatic breast carcinoma (Genentech/Roche). His third contribution to biomedicine, SU11248/SUTENT, was conceived on the basis of discoveries in his laboratory at the Max Planck Institute of Biochemistry and developed by SUGEN/Pharmacia and Pfizer. It was recently approved by the FDA (1/2006) and the EMEA (7/2006) for the treatment of Gastro Intestinal Stromal Tumors and Renal Cell Carcinoma (Pfizer).

Since 1988, Professor Ullrich has been Director of the Department of Molecular Biology at the Max-Planck-Institute of Biochemistry in Martinsried and in addition since 2004 he is Research Director of the Singapore OncoGenome Project. He is an Honorary Professor of the Second Military Medical University (Shanghai, China) and the University of Tuebingen (Germany) and elected member of the European Molecular Biology Organization (EMBO), the German Academy of Natural Scientists "Leopoldina" and the American Academy of Arts and Sciences (AAAS).

Among numerous other honors and awards, Professor Ullrich received the Robert Koch Prize the Bruce F. Cain Memorial Award of the American Association of Cancer Research and the King Faisal Prize of Medicine. Because of his major contributions to Science he has been appointed to advisory boards of internationally renowned institutions such as the Wistar Institute (USA), the Biomedicum (Finland), the Max-Delbrueck-Center for Molecular Medicine (Germany) and the International Advisory Council of the EDB (Singapore). His scientific work has been published in more than 500 articles in international journals and with over 58,000 citations he is one of the ten most cited scientists over the past 25 years worldwide.

Professor Ullrich has been a leader in international Biotechnology development with activities stretching from Germany, to the USA, Singapore and Australia. He is co-founder of three Biotech companies - SUGEN Inc. (USA), Axxima Pharmaceuticals AG (Germany), U3 Pharma AG (Germany) and Kinaxo (Germany). In addition he has served on numerous Boards of Directors and Science Advisory Boards of Biotech companies including SUGEN, Inc. (USA), BioImage (Denmark), Bionomics (Australia), Cryptome Pharmaceuticals (Australia) and S*Bio (Singapore) and pharmaceutical companies (Boehringer Ingelheim, Germany).

Since 2000 he is a Biotech Advisor of the Economic Development Board of the Singapore Government and its Biotech Investment organization, BioOneCapital. Moreover, he is a founding member of the Board of Directors of the Bavarian Biotech Management Company BioM. In 2001 Time Magazine Europe has named Professor Ullrich as one of 25 European "tech leaders who are changing how we work, live and play".

Dr. Urban has been working to reduce mortality from breast and ovarian cancer for over 15 years, studying ways to improve the use, performance and efficacy of breast and ovarian cancer screening tools including mammography and the blood test CA125. She is particularly interested in the discovery, development and validation of novel markers detectable in serum, for use in cancer risk assessment and screening. She is best known for her evaluation of candidate serum markers for ovarian cancer, including HE4 and Mesothelin, and her analysis of the cost-effectiveness of screening for ovarian cancer.

Dr. Urban earned her BA from Simmons College in 1970, and in 1973 earned a MS in Biostatistics followed by a ScD in 1978 in Health Services and Biostatistics, both from the Harvard School of Public Health. She joined the University of Washington in 1978 where she is Professor of Health Services Research, and the Fred Hutchinson Cancer Research Center in 1984 where she heads the Gynecologic Cancer Research Program and is a Member of the Molecular Diagnostics Program in the Public Health Sciences Division. In 1999 she was awarded a Specialized Program of Research Excellence (SPORE) in Ovarian Cancer by the National Cancer Institute (NCI) to conduct translational research that is now in its eighth year of funding. In 2002 she was awarded a Center for the Evaluation of Biomarkers for the Early Detection of Breast Cancer by the Department of Defense Breast Cancer Research.

Jane Visvader heads the developmental and molecular biology group in the Victorian Breast Cancer Research Consortium, located at The Walter and Eliza Hall Institute. Her research has focussed on understanding the epithelial hierarchy in the breast tissue and cell types that are predisposed to oncogenesis. This work has led to the prospective isolation of mouse mammary stem cells and luminal progenitor cells, thus providing a fundamental base for future studies in this field. Another major objective of the laboratory is to define transcription factors important for normal mammary gland development and perturbations that arise in breast cancer. A long-standing interest in transcriptional regulators has resulted in important findings in hematopoiesis and mammary development. Jane has been awarded a NHMRC (Australia) Senior Research Fellowship and serves on the Medical and Scientific Advisory Committee of the Cancer Council, Victoria.

Jane completed her PhD in the Department of Biochemistry, University of Adelaide, and has held postdoctoral positions at the Salk Institute, San Diego and Childrens' Hospital, Boston/Harvard Medical School.

Professor Karen Vousden is the Director of the Cancer Research UK Beatson Institute in Glasgow. The Beatson Institute carries out a program of world-class science directed at understanding key aspects of cancer cell behavior and provides a state of the art facility where basic and clinical scientists can work together to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. Karen's own research focuses on the tumour suppressor protein p53, which plays an important role in cancer prevention. Karen’s lab is interested in understanding the signals that induce p53 and the functions of p53 that contribute to its ability to prevent cancer progression. Ultimately, they hope to be able find ways to use an understanding of the p53 pathway for cancer therapy.

Karen received her Ph.D. in Genetics from the University of London, followed by postdoctoral fellowships with Chris Marshall at the Institute of Cancer Research in London and Douglas Lowy at the National Cancer Institute in the USA. She then became head of the Human Papillomavirus group the Ludwig Institute for Cancer Research in London before moving back to the NCI in 1995, where she was Director of the Molecular Virology and Carcinogenesis Section at the ABL-Basic Research programme and then Chief of the Regulation of Cell Growth Laboratory. She took up her current position in 2002.

Karen has been elected as a fellow of the Royal Society, the Royal Society of Edinburgh, EMBO, the Academy of Medical Sciences, the European Academy of Sciences and the American Association for the Advancement of Science. She has also received honorary DScs from the Universities of London and Strathclyde. Karen’s awards include the Tenovus Gold Medal, the Sir Frederick Gowland Hopkins Medal, the Royal Medal from the Royal Society of Edinburgh and she was made a Commander of the British Empire for services to clinical science. She is presently on the Board of Directors of the AACR.

  • Anton Wellstein
  • Anton Wellstein

    Professor of Oncology and Pharmacology and Associate Director for Basic Research at the Lombardi Comprehensive Cancer Center, Georgetown University

    Email: wellstea@georgetown.edu

Dr. Wellstein trained as an MD & PhD (Pharmacology) in Germany and then on a sabbatical at NCI/NIH to study growth factor signaling in breast cancer in Marc E Lippman’s lab. He was then recruited to the faculty of Georgetown University in the Departments of Pharmacology and Oncology, where he is a tenured Professor. His lab discovered that the receptor for the growth factor pleiotrophin is ALK (anaplastic lymphoma kinase) and defined the role of secreted binding proteins for FGF (FGFBPs) in cancer, physiology and development. Dr. Wellstein’s work is focused on tumor / stromal interaction with a particular emphasis on the activity of FGFs and the pleiotrophin/ALK signaling pathways. His major interest is in mechanisms of cancer invasion and metastasis. His laboratory studies cellular, molecular and biochemical signal transduction mechanisms in vitro as well as in tumors, transgenic and knockout animal models and clinical samples. Published >170 papers.

Otmar D. Wiestler was born in Freiburg, Germany on November 6, 1956. He studied Medicine at the University of Freiburg and received his M.D. in 1984. From 1984 to 1987 he worked as postdoc at the Department of Pathology, University of California in San Diego / USA. After a four year period as senior resident and assistant Professor in Neuropathology at the University of Zurich / Switzerland, he moved to the University of Bonn in 1992, where he was appointed as Professor of Neuropathology and Head of the Department of Neuropathology. At this University, he established a major neuroscience research center. In January 2004 he joined the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) in Heidelberg as Chairman and Scientific Member of the Management Board.

Otmar D. Wiestler has served on a number of scientific and professional boards, as Head of the German Brain Tumor Reference Center in Bonn, Chairman of the BONFOR research committee at the University of Bonn, President of the German Society of Neuropathology and Neuroanatomy, Head of the Review Board Theoretical Medicine of the Deutsche Forschungsgemeinschaft (DFG), Member of the Medical Advisory Board of Deutsche Krebshilfe (German Cancer Aid) and as CEO of the Life & Brain Neuroscience platform in Bonn.

Otmar D. Wiestler contributed more than 300 papers and book chapters to the scientific literature. He has also served as an editorial board member of several international journals, among them Acta Neuropathologica (Editor), Brain Pathology Cancer Letters, Carcinogenesis, Journal of Neurology, Neuropathology & Applied Neurobiology.

Since 2001 he is an elected member of the German Life Science Academy LEOPOLDINA.

  • Paul Workman
  • Paul Workman

    Deputy Chief Executive of The Institute of Cancer Research (ICR), London
    Head of the Division of Cancer Therapeutics
    Harrap Professor of Pharmacology and Therapeutics
    Director of Cancer Research UK Cancer Therapeutics Unit at ICR

    Email: paul.workman@icr.ac.uk

Professor Paul Workman is Deputy Chief Executive of The Institute of Cancer Research (ICR),London, Head of its Division of Cancer Therapeutics and Harrap Professor of Pharmacology and Therapeutics. Paul is also Director of Cancer Research UK Cancer Therapeutics Unit at ICR – the largest non-profit cancer drug discovery group in the world.

Paul is a pioneer in the discovery of molecular targeted therapies. He is especially renowned for his innovative personal research in the discovery, chemical biology and molecular pharmacology of HSP90 and PI3 kinase inhibitors and as the originator of the widely used Pharmacologic Audit Trail for biomarker-led drug development. Paul has also been the founder of two biotechnology companies, Piramed Pharma and Chroma Therapeutics.

Since 2005, under Paul’s leadership the Cancer Therapeutics Unit has discovered 16 drug candidates, including inhibitors of the molecular chaperone HSP90, PI3 kinase and PKB/AKT. Six of the Unit’s drugs are currently undergoing Phase I/II clinical trials and abiraterone was approved in 2012 for late-stage prostate cancer. Paul has published over 470 research publications and has received numerous honours and awards. He has been elected as a Fellow of the Academy of Medical Sciences and was the leader of the ICR/Royal Marsden Hospital Team that won the prestigious American Association for Cancer Research Team Science Award in 2012. He also received the 2012 Royal Society of Chemistry World Entrepreneur Award and the 2010 Royal Society of Chemistry George and Christine Sosnovsky Award in Cancer Therapy.

  • Huanming Yang

    President & Professor
    Beijing Genomics Institute (BGI), Shenzhen, China

    E-mail: yanghm@genomics.org.cn

Dr. Yang received his Ph.D. from University of Copenhagen, Denmark, in 1988, and obtained his postdoctoral trainings in France and USA. As one of the co-founders of BGI (formerly Beijing Genomics Institute), he and his collaborators have made a significant contribution to the HGP and HapMap projects, as well as to sequencing and analysing genomes of rice, cucumber, chicken, silkworm, giant panda, ant, maize, soybean, and many microorganisms since 1999. BGI, together with its collaborators, has published the first Asian's genome, human pan-genome, human ancient genome, and human gut metagenomes by means of new-generation sequencing technology and innovative bioinformatic tools recently in Science, Nature and other internationally prestigious journals. BGI now has become one of the most influential genomics centers in the world and a major contributor to the International 1000 Genomes Project.

Dr. Yang has received many awards and honors, including Research Leader of the Year by Scientific American in 2002 and Award in Biology by the Third World Academy of Sciences (TWAS); in 2006. He was elected as a foreign member of EMBO in 2006, an academician of Chinese Academy of Sciences in 2007, a fellow of TWAS in 2008, a foreign academician of Indian Academy of Sciences in 2009.

Yosef Yarden is professor in the Department of Biological Regulation at the Weizmann Institute of Science, Rehovot, Israel. He received his BSc at the Hebrew University, Jerusalem, and his PhD at the Weizmann Institute. He trained at Genetech Inc. and in the Whitehead Institute (MIT) before establishing his own laboratory at the Weizmann Institute. Dr Yarden's research career has been devoted to understanding the role of receptor tyrosine kinases (RTKs) in human cancer. He has been involved in many crucial developments in this field, including purification and molecular cloning of the first RTKs, namely the EGF-receptor, c-Kit, PDGF-receptor and several receptors for FGFs. In addition, he discovered the neuregulin family of growth factors. On the functional aspect of RTKs, he discovered the universal initiating step of signaling, namely the process of receptor dimerization. In this context, Yarden resolved the role of HER2 in tumor development as a shared herterodimerizing subunit of other receptors. He also discovered the last step in RTK signaling, namely the process leading to receptor ubiquitinylation and sorting for degradation in lysosomes. He is a member of the European Molecular Biology Organization and the Asia-Pacific International Molecular Biology Network. He has received numerous awards for his work, including the H. Dudley Wright Research Award in Biomembranes, the Somech Sachs Prize in Chemistry, the Andre Lwoff Prize, the Lombroso Award for Cancer Research, the Michael Bruno Prize, the Teva Founders' Prize, and the MERIT Award of the U.S. National Cancer Institute. Currently, Dr. Yarden is the Dean of the Feinberg Graduate School. In the past he served as Vice President for Academic Affairs of the Weizmann Institute of Science, Director of the M.D. Moross Cancer Research Institute, and Dean of the Faculty of Biology.

  • Timothy J. Yeatman

    Professor of Surgery and Interdisciplinary Oncology, Associate Center Director for Translational Research, and Director of Total Cancer Care at H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, USA

    E-mail: yeatman@gibbscc.org

Dr. Yeatman has focused his research on the management of gastrointestinal malignancies with a special research emphasis on using genome scale microarrays to identify the molecular signatures of cancer that provide diagnosis, prognosis and response to therapy. He found that microarray was 88 percent accurate in predicting all tumor types. The results of his investigation, the first such work to be reported in this depth, appeared in the January 2004 issue of the American Journal of Pathology. Recently, Dr. Yeatman has been appointed to the Directorship of Total Cancer Care, a large research project that will lead to personalized cancer care. Dr. Yeatman has received numerous honors and awards including the James IV Association of Surgeons Traveling Fellowship, Europe 2001; the Center Director's Award for Outstanding Research at Moffitt Cancer Center (1998, 1997, 1995); and the James Ewing Foundation Trainee Award, Society of Surgical Oncology, 1997. Additionally, Dr. Yeatman has published more than 120 articles in the top peer-reviewed journals in his field including the prestigious Nature Genetics, Nature Reviews Cancer, as well as the Journal of the National Cancer Institute, and Cancer Research. Dr. Yeatman has been continuously funded over the course of the past 12 years through grants from the NCI and the American Cancer Society. Dr. Yeatman earned his M.D. at Emory University; Surgical Internship & Residency at the University of Florida; and Surgical Oncology Fellowship at the MD Anderson Cancer Center.

Dr Zhan is also the Director of the National Laboratory of Molecular Oncology and the Chief Scientist of 973 the National Fundamental Program (cancer research field). He received his medical degree in Suzhou University Medical College in 1982 and completed his graduate study in the Peking Union Medical College in 1987. From 1989-1995, Dr. Zhan had his postdoctoral training in the University of California San Francisco, University of Texas Southwestern Medical Center at Dallas and the National Cancer Institute, NIH. In 1996, he was promoted to Senior Staff Fellow in the National Cancer Institute, NIH. In 1998, Dr. Zhan started to serve in the University of Pittsburgh Cancer Institute as a Principal Investigator and a tenure-track faculty in the University of Pittsburgh School of Medicine, Department of Radiation Oncology and the Department of Molecular Genetics and Biochemistry. In 2003, he was promoted to Associate Professor with tenure. Dr. Zhan took a position at CAMS in early 2002, and he is currently a Professor in Peking Union Medical College and a Senior Investigator in Chinese Academy of Medical Sciences Cancer Institute, Beijing, China. Over the past several years, he obtained the scholarship of "Changjiang Scholar Program" and National Outstanding Youth Funding. Dr. Zhan's research interest focuses on the molecular pathways involved in the control of cell cycle checkpoint and apoptosis after DNA damage. He is also interested in signalling pathways involved in regulation of stress-inducible genes. His research had successfully attracted multiple grants from extramural funding agencies, including National Institutes of Health (NIH R01), Department of Defence (DOD grant) and American Cancer Society during his appointment in the States.

Dr. Zhan's has totally published 65 peer-reviewed scientific papers. Most of his publications are in prestigious journals, including Cell, Journal of Molecular and Cellular Biology, Science, Cancer Research, Oncogene, Journal of Biological Chemistry and the Proceedings of the National Academy of Sciences. Dr. Zhan has been the first or corresponding author in 25 papers of his total publications and many of his papers have been highly cited in the biomedical field. Currently, his publications have been cited more than 7000 times (SCI database), including a single paper citation as high as 2600 times. Dr. Zhan has also been invited to present his work at a number of universities, professional meetings and grand rounds. He is a member in the editorial board for Journal of Cancer Biology and Therapy and a reviewer for Cancer Research, Oncogene, Journal of Molecular Pharmacology, Experimental Cell Research, Radiation Research, and Mutation Research. Dr. Zhan is also a member of the American Association for Cancer Research and the American Association for the Advancement of Science.

Dr. Laurence Zitvogel is the Research Director at Institut National de la Santé et Recherche Médicale in a laboratory located at Institut GrustaveRoussy, Villejuif, France. She graduated in 1992 with a degree in Medical Oncology from the School of Medicine of the University of Paris, France. She began her scientific career at the University of Pittsburgh, USA working under Michael Lotze. Her expertise is mainly dendritic cell and innate effector biology and relevance during tumor development, as well as exosome-based vaccine designs.


From January 1, 2017 Molecular Oncology is published by FEBS Press and Wiley

Molecular Oncology has become fully Open Access, allowing everyone to read the journal irrespective of speciality, host institution or location. All articles are published under the Creative Commons Attribution License (CC BY) to meet funders’ requirements worldwide.


Citation Metrics

  • 2016 2-Year Impact Factor: 5.314
  • 2016 5-Year Impact Factor: 5.957
  • 2016 CiteScore: 5.25

Editorial Board

Editor-in-Chief Julio Celis

Senior Associate Editors Anne-Lise Børresen-Dale and  Ulrik Ringborg 

Managing Editor Jose Moreira

Future Events in Oncology

30-31 January, 2018, London, United Kingdom
01-03 February, 2018, Amsterdam, Netherlands
05-07 February, 2018, Milan, Italy
14-16 February, 2018, Cape Town, South Africa
01-02 March, 2018, Valencia, Spain
05-07 March, 2018, Paris, France
12-14 March, 2018, Oxford, United Kingdom
19-21 March, 2018, Berlin, Germany
21-23 March, 2018, Barcelona, Spain
23-29 March, 2018, Barcelona, Spain
11-14 April, 2018, Geneva, Switzerland
20-24 April, 2018, Barcelona, Spain
27-29 April, 2018, Lugano, Switzerland
21-26 May, 2018, Ohio, USA
04-06 June, 2018, Amsterdam, Netherlands
16-22 June, 2018, Zeist, Netherlands
22-23 June, 2018, TBC, Dominican Republic